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Summary
Background Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer 
survival by central analysis of population-based registry data, as a metric of the eﬀ ectiveness of health systems, and to 
inform global policy on cancer control.
Methods Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 
25·7 million adults (age 15–99 years) and 75 000 children (age 0–14 years) diagnosed with cancer during 1995–2009 
and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast 
(women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control 
procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted 
for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic 
origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights.
Findings 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For 
patients diagnosed during 2005–09, survival for colon and rectal cancer reached 60% or more in 22 countries around 
the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer 
remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15–19% 
in North America, and as low as 7–9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate 
cancer have occurred in many countries: survival rose by 10–20% between 1995–99 and 2005–09 in 22 countries in 
South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria 
and Thailand to 95% or more in Brazil, Puerto Rico, and the USA.  For cervical cancer, national estimates of 5-year 
survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 
1995–99 and 2005–09 have generally been slight. For women diagnosed with ovarian cancer in 2005–09, 5-year 
survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach 
cancer in 2005–09 was high (54–58%) in Japan and South Korea, compared with less than 40% in other countries. By 
contrast, 5-year survival from adult leukaemia in Japan and South Korea (18–23%) is lower than in most other 
countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as 
high as 90% in Canada and four European countries, which suggests major deﬁ ciencies in the management of a 
largely curable disease.
Interpretation International comparison of survival trends reveals very wide diﬀ erences that are likely to be attributable 
to diﬀ erences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer 
survival should become an indispensable source of information for cancer patients and researchers and a stimulus 
for politicians to improve health policy and health-care systems.
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Introduction
The global burden of cancer is growing, particularly in 
countries of low and middle income. The need to 
implement eﬀ ective strategies of primary prevention is 
urgent.1,2 Prevention is crucial but long term. If WHO’s 
global target of a 25% reduction in deaths from cancer 
and other non-communicable diseases in people aged 
30–69 years is to be achieved by 2025 (referred to as 
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25 × 25),3 we will need not only more eﬀ ective prevention 
(to reduce incidence) but also more eﬀ ective health 
systems (to improve survival).4
In the ﬁ rst international comparison of cancer survival, 
a transatlantic study of patients diagnosed during 
1945–54, survival for 12 cancers in three US states was 
typically higher than in six European countries.5 In 2008, 
a global comparison of population-based cancer survival 
(CONCORD) showed very wide variations in survival 
from cancers of the breast (women), colon, rectum, and 
prostate.6 That analysis included 1·9 million adults 
(age 15–99 years) diagnosed with cancer during 1990–94 
and followed up until 1999 from 31 countries (16 with 
100% population coverage) on ﬁ ve continents.
Three large international comparisons of cancer 
survival have been published since 2008. The European 
cancer registry study on survival (EUROCARE)-5 
provided survival estimates for all cancers for patients 
diagnosed during 2000–07 in 29 countries in Europe.7 In 
SurvCan (cancer survival in Africa, Asia, the Caribbean, 
and Central America), relative survival estimates were 
reported for patients diagnosed during 1990–2001 in 
12 low-income and middle-income countries.8 The 
International Cancer Benchmarking Partnership 
published survival estimates for four common cancers 
for patients diagnosed during 1995–2007 in six high-
income countries.9 These three studies diﬀ er with respect 
to geographic and population coverage, calendar period, 
and analytical methods and do not enable worldwide 
comparison of cancer survival.
Surveillance of cancer survival is seen as important by 
national and international agencies, cancer patient 
advocacy groups, departments of health, politicians, and 
research agencies. Cancer survival research is being used 
to formulate cancer control strategies,9 to prioritise cancer 
control measures,10 and to assess both the eﬀ ectiveness11,12 
and cost-eﬀ ectiveness13 of those strategies.
We designed CONCORD-2 to initiate long-term 
worldwide surveillance of cancer survival on the broadest 
possible basis. Our aim is to analyse progress toward the 
overarching goal in the Union for International Cancer 
Control’s World Cancer Declaration 2013: “there will be 
major reductions in premature deaths from cancer and 
improvements in quality of life and cancer survival”.14
Methods
Cancer registries
We identiﬁ ed population-based cancer registries that were 
operational in 2009 and had either published reports on 
survival or were known to follow up registered cancer 
patients to establish their vital status. Many registries had 
met quality criteria for inclusion in either the quinquennial 
compendium Cancer Incidence in Five Continents,15,16 
published by the International Association of Cancer 
Registries (IACR) and the International Agency for 
Research on Cancer (IARC), or similar compendia; other 
registries were established more recently.
We invited all these registries to contribute data for 
patients diagnosed during all or part of the 15-year 
period 1995–2009, including data on their vital status at 
least 5 years after diagnosis, or at Dec 31, 2009, or a 
later year. Of 395 registries invited, 306 (77%) agreed to 
participate: of these, 24 (8%) did not submit data, either 
because of resource constraints (n=4), legal constraints 
(1) or reversal of the original decision (3), or because 
they could not provide complete follow-up data (6) or 
did not respond to further communication (10). 
We excluded three registries because they provided data 
that did not adhere to the protocol and could not be 
rectiﬁ ed, leaving 279 participating registries (71% of 
those invited).
Among the cancers suggested by participating registries, 
the ten we prioritised for study (referred to as index sites) 
accounted collectively for almost two-thirds of the 
estimated global cancer burden in 2008, both in developed 
and developing countries.4 They comprised cancers of the 
stomach, colon, rectum, liver, lung, breast (women), 
cervix, ovary, and prostate in adults (age 15–99 years), and 
leukaemia in adults, and precursor-cell acute lympho-
blastic leukaemia in children (age 0–14 years).
Ethics approval
We obtained approval for CONCORD-2 from the Ethics 
and Conﬁ dentiality Committee of the UK’s statutory 
National Information Governance Board (now the Health 
Research Authority; ECC 3-04(i)/2011) and the National 
Health Service (NHS) research ethics service (southeast; 
11/LO/0331). We obtained separate statutory or ethics 
approval (or both) in more than 40 other jurisdictions to 
secure the release of data. Registries in all other 
jurisdictions obtained their own ethics approval locally.
We applied strict security constraints to the 
transmission of data ﬁ les. We gave every registry a set of 
unique numeric codes for the name of every ﬁ le; these 
codes have no meaning outside the CONCORD-2 study. 
All data ﬁ elds were numeric or coded. We developed a 
ﬁ le transmission utility deploying 256-bit advanced 
encryption security, with random, strong, one-time 
passwords that were generated automatically at the point 
of data transmission but sent separately, thus eliminating 
the need for email or telephone exchanges to conﬁ rm 
passwords. We also provided free access to a similar 
commercial utility (HyperSend; Covisint, Detroit, MI, 
USA) that complies with US federal law on the secure 
transmission of sensitive health data.
Protocol
We ﬁ nalised the protocol (in which we deﬁ ned the data 
structure, ﬁ le transmission procedures, and statistical 
analyses) after a 2-day meeting in Cork, Ireland, in 
September, 2012, with 90 members of the CONCORD 
Working Group from 48 countries (the protocol was 
revised by October, 2012). English poses a communication 
barrier in many countries; therefore, native speakers 
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translated the protocol into Chinese (Mandarin), 
Portuguese, and Spanish, and other native speakers did 
back-translation to check the translation against the 
English original. We made the protocol available in all 
four languages. We held protocol workshops in Argentina 
(for Spanish-speaking South American researchers), 
Brazil, China, India, Japan, Puerto Rico, Russia, and the 
USA (for North America), which we followed up with 
conference calls and online seminars. We responded to 
telephone or email queries in Chinese, English, French, 
Italian, Portuguese, and Spanish.
We deﬁ ned countries, states, and world regions by 
their UN names and codes (as of 2007).17 Only Cuba and 
Puerto Rico provided data from the Caribbean and 
Central America so we grouped them with South 
America as America (Central and South). We wrote this 
Article and prepared the maps without prejudice to the 
status, boundaries, or name of any country, territory, or 
region. We have shortened some names for convenience 
(eg, Korea for South Korea), which does not have any 
political signiﬁ cance. We created world maps and 
27 regional maps in ArcGIS version 10, using digital 
boundaries (shapeﬁ les) of countries and subnational 
regions from the Database of Global Administrative 
Areas (GADM 2.0).18 We obtained national populations 
for 2009 from the UN Population Database17 or national 
authorities (Canada, Portugal, and the UK) and 
subnational populations from the relevant registries.
We deﬁ ned solid tumours by anatomical site 
(topography) and leukaemia by morphology (table 1). 
We coded topography and morphology according to the 
International Classiﬁ cation of Diseases for Oncology 
(3rd edn; ICD-O-3).19 For ovarian cancer, we included the 
fallopian tube, uterine ligaments, and adnexa, and the 
peritoneum and retroperitoneum, where high-grade 
serous ovarian carcinomas are often detected. 
We excluded Kaposi’s sarcoma and solid tumours with 
lymphoma morphology.
The classiﬁ cation of leukaemias and lymphomas has 
changed since the mid-1990s. To minimise diﬀ erences in 
the range of leukaemia subtypes included in our analyses, 
we asked registries to provide data for all haemopoietic 
malignant diseases in adults and children, as deﬁ ned by 
the ICD-O-3 morphology code range 9590–9989. 
In consultation with specialists in the cancer registry-
based project on haematologic malignancies 
(HAEMACARE) group,20 we selected subtypes of adult 
leukaemia from nine morphology groups,21 excluding 
myelodysplastic and myeloproliferative neoplasms such 
as chronic myeloid leukaemia (appendix p 2). Precursor-
cell acute lymphoblastic leukaemia is the most common 
form of leukaemia in children; we included 
HAEMACARE group 15—a relatively homogeneous 
group comprising precursor-cell lymphoblastic 
lymphoma and precursor-cell lymphoblastic leukaemia 
(B-cell, T-cell, and not otherwise speciﬁ ed), and we refer 
to these six entities as acute lymphoblastic leukaemia.22
For survival analyses, we included only invasive primary 
malignant diseases (ICD-O-3 behaviour code 3). To 
facilitate quality control and comparisons of the intensity 
of early diagnostic and screening activity, however, we 
asked registries to submit data for all solid tumours at 
each index site, including those that were benign 
(behaviour code 0), of uncertain or borderline malignancy 
(1), or in situ (2).
We asked registries to submit full dates (day, month, 
year) for birth, diagnosis, and death or last known vital 
status, both for quality control and to enable comparable 
estimation of survival.23 When the day of diagnosis or the 
day or month of birth or last known vital status were 
missing, we developed an algorithm to standardise the 
imputation of missing dates for all populations (details 
available on request). Participating registries completed a 
detailed question naire on their methods of operation, 
including data deﬁ nitions, data collection procedures, 
coding of anatomical site, morphology and behaviour, 
the tracing of registered cancer patients to ascertain their 
vital status, and how tumour records are linked with data 
on vital status.
We included patients who were diagnosed with two or 
more primary cancers at diﬀ erent index sites during 
1995–2009 in the analyses for each cancer—eg, colon 
cancer in 2000, breast cancer in 2005. We measured 
survival from the date of diagnosis until the date of death, 
or loss to follow-up, or censoring. When two or more 
See Online for appendix
Topography or morphology codes* Description
Stomach C16·0–C16·6, C16·8–C16·9 Stomach
Colon C18·0–C18·9, C19·9 Colon and rectosigmoid junction
Rectum C20·9, C21·0–C21·2, C21·8 Rectum, anus, and anal canal
Liver C22·0–C22·1 Liver and intrahepatic bile ducts
Lung C34·0–C34·3, C34·8–C34·9 Lung and bronchus
Breast 
(women)
C50·0–C50·6, C50·8–C50·9 Breast
Cervix C53·0–C53·1, C53·8–C53·9 Cervix uteri
Ovary† C48·0–C48·2, C56·9, C57·0–C57·4, C57·7–C57·9 Ovary, fallopian tube, and uterine 
ligaments, other and unspeciﬁ ed 
female genital organs, peritoneum 
and retroperitoneum
Prostate C61·9 Prostate gland
Leukaemia 
(adults)‡
9670, 9687, 9727, 9728, 9729, 9800, 9801, 9805, 
9820, 9823, 9826, 9832, 9833, 9835, 9836, 9837, 
9840, 9860, 9861, 9866, 9867, 9870, 9871, 9872, 
9873, 9874, 9891, 9895, 9896, 9897, 9910, 9920, 
9930, 9931, 9940, 9984, 9987
Leukaemia
Leukaemia 
(children)‡
9727, 9728, 9729, 9835, 9836, 9837 Precursor-cell acute lymphoblastic 
leukaemia
*International Classiﬁ cation of Diseases for Oncology, 3rd edn (ICD-O-3).19 We deﬁ ned solid tumours with topography 
(anatomical site) codes. †Includes peritoneum and retroperitoneum (C48·0–C48·2), where ovarian cancers of 
high-grade serous morphology are frequently detected; also includes the fallopian tube, uterine ligaments, and adnexa 
(C57·0–C57·4), and other and unspeciﬁ ed female genital organs (C57·7–C57·9). ‡We deﬁ ned adult leukaemia subtypes 
with morphology codes in HAEMACARE groups 6, 11, 15, 17, 18, 19, 20, 21, and 22 (appendix p 2).20 The six 
morphology codes used to deﬁ ne precursor-cell acute lymphoblastic leukaemia (referred to as acute lymphoblastic 
leukaemia) in children are those in HAEMACARE group 15 only.
Table 1: Deﬁ nition of malignant diseases 
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primary malignant diseases occurred at the same index 
site during 1995–2009, we included the ﬁ rst cancer only. 
We retained the most complete record for patients with 
synchronous primary cancers in the same organ.
North American registries deﬁ ne multiple primary 
cancers under the rules of the Surveillance, Epidemiology 
and End Results (SEER) programme,24 whereas registries 
in the European Network of Cancer Registries (ENCR) 
and elsewhere generally use the rules of the IACR,25 
which are more conservative. The North American 
Association of Central Cancer Registries (NAACCR) 
prepared a program to enable all North American 
registries to recode their entire incidence databases to 
the IACR multiple primary rules, before their datasets 
for 1995–2009 were extracted for CONCORD-2.
Quality control
The quality and completeness of cancer registration data 
can aﬀ ect both incidence and survival estimates and, 
thus, the reliability of international comparisons.26 
We developed a suite of quality control programs,27 
extending the checks used in the ﬁ rst CONCORD study,6 
cross-checked with those used in the EUROCARE 
study,28 IARC/IACR tools for cancer registries,29 and 
WHO’s classiﬁ cation of tumours.22,30–32 We applied these 
checks systematically in three phases and sent registries 
a detailed report on how to revise and resubmit their 
data, if needed, after every phase.
First, we sent registries a protocol adherence report 
that showed, for every cancer, the proportion of tumour 
records that were coded in compliance with the protocol. 
Second, we checked the data in every tumour record for 
logical coherence against 20 sets of criteria, including 
eligibility (eg, age, tumour behaviour), deﬁ nite errors 
(eg, sex-site errors and invalid dates or date sequence), 
and possible errors including a wide range of 
inconsistencies between age, tumour site, and 
morphology.27 We sent registries exclusion reports that 
showed, for every index cancer and calendar period, the 
number of tumour records in each category of deﬁ nite or 
possible error, the number of tumours registered from a 
death certiﬁ cate only or detected at autopsy, and the 
number of patients whose data could be included 
in survival analyses. When we identiﬁ ed errors in 
classiﬁ cation, coding, or pathological assignment, 
we asked registries to correct and resubmit their data. 
Finally, we analysed: the proportion of tumour records 
with morphological veriﬁ cation or non-speciﬁ c 
morphology; distributions of the day and month of birth, 
diagnosis, and last known vital status; and proportions of 
patients who died within 30 days, were reported as lost to 
follow-up, or were censored within 5 years of diagnosis.
Follow-up for vital status
Cancer registries use various methods to ascertain the 
vital status (alive, dead, emigrated, lost to follow-up) of 
registered cancer patients. In countries with limited 
administrative infrastructure, so-called active follow-up 
can be used to establish vital status via direct contact with 
the patient, the family, or a local authority (eg, a village 
headman), or by home visit. Many registries in both 
high-income and low-income countries also seek 
information from the hospital or the treating clinician in 
hospital or primary care.
Most registries link their database with a regional or 
national index of deaths, using identiﬁ ers such as name, 
sex, date of birth, and identity number. Tumour records 
that match to a death record are updated with the date of 
death. Many registries also use other oﬃ  cial databases 
(eg, hospital and primary care databases, social insurance, 
health insurance, drivers’ licences, and electoral registers) 
to establish the date on which a patient was last known or 
believed to have been alive, to have migrated within the 
country, or to have emigrated to another country. Cancer 
registrations are updated with the vital status and the 
date of last known vital status. These methods are 
typically summarised as passive follow-up.
Some registries receive information on the vital status 
of all registered patients on an almost continuous basis, 
or at least every month or every 3 months. Other registries 
seek to trace the vital status of patients registered in a 
particular calendar year only, 1 year or even 5 years after 
the end of that year: this approach can increase the 
proportion of patients lost to follow-up. It also means that 
5-year survival estimates for more recently diagnosed 
patients cannot be obtained, even with the period 
approach.
We asked all 279 participating registries how they 
ascertained the vital status of registered cancer patients. 
Of 243 registries that responded to the question, 
147 (60%) stated that they used only passive follow-up, 
92 (38%) that they used both passive and active follow-up, 
and four (2%) only active follow-up.
Statistical analysis
Most registries submitted data for patients diagnosed 
from 1995 to 2009, with follow-up to 2009 or later; some 
registries only began operation after 1995 or provided 
data for less than 15 years. We were able to estimate 
5-year survival using the cohort approach for patients 
diagnosed in 1995–99 and 2000–04, because in most 
datasets, all patients had been followed up for at least 
5 years. We used the period approach33 to estimate 5-year 
survival for patients diagnosed during 2005–09, because 
5 years of follow-up data were not available for all patients 
(appendix p 174).
We estimated net survival up to 5 years after diagnosis 
for both adults and children. Net survival represents the 
cumulative probability that the cancer patients would 
have survived a given time, say 5 years or more after 
diagnosis, in the hypothetical situation that the cancer 
was the only possible cause of death. Net survival can be 
interpreted as the proportion of cancer patients who 
survive up to that time, after eliminating other causes of 
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death (background mortality). We used the recently 
developed Pohar Perme estimator34 of net survival imple-
mented with the program stns35 in Stata version 13.36 This 
estimator takes unbiased account of the fact that older 
patients are more likely than younger patients to die 
from causes other than cancer—ie, that the competing 
risks of death are higher for elderly cancer patients.
To control for the wide diﬀ erences in background 
mortality between participating jurisdictions and over 
time, we constructed 6514 life tables of all-cause mortality 
in the general population of each country or the territory 
covered by each participating registry, by age (single 
year), sex, and calendar year of death, and by race or 
ethnic origin in Israel (Arab, Jewish), Malaysia (Chinese, 
Malay, Indian), New Zealand (Māori, non-Māori), and the 
USA (Black, White). The method of life table construction 
depended on whether we received raw data (numbers of 
deaths and populations) or mortality rates, and on 
whether the raw data or the mortality rates were by single 
year of age (so-called complete) or by 5-year or 10-year 
age group (abridged). We checked the life tables by 
examination of age-sex-mortality rates, life expectancy at 
birth (appendix p 175), the probability of death in the age 
bands 15–59 years, 60–84 years, and 85–99 years and, 
where necessary, the model residuals.
Of the 279 participating registries, 21 provided 
complete life tables that did not need interpolation or 
smoothing, for each calendar year. For 172 registries, 
we obtained raw data from either the registry, the 
relevant national statistical authority, or the Human 
Mortality Database.37 We derived life tables for 1996 and 
2010 if possible, each centred on three calendar years of 
data (eg, 1995–97, 2009–11) to increase the robustness of 
the rates. We modelled raw mortality rates with Poisson 
regression and ﬂ exible functions to obtain smoothed 
complete life tables extended up to age 99 years. We then 
created life tables for every calendar year from 1997 to 
2009 by linear interpolation between the 1996 and 2010 
life tables.38 Rather than extrapolate, we used the 1996 
life table for 1995.
62 of 279 registries provided abridged mortality rates, 
or complete mortality rates that were not smoothed. 
We used the Ewbank relational model39 with three or 
four parameters to interpolate (if abridged) and smooth 
the mortality rates for the registry territory against a 
high-quality smooth life table for a country with a similar 
pattern of mortality by age. We could not obtain reliable 
data on all-cause mortality for 24 registries. We took 
national life tables published by the UN Population 
Division40 and interpolated and extended them to 
age 99 years with the Elandt-Johnson method.41
For each country and registry, we present estimates of 
age-standardised net survival for each cancer at 5 years 
after diagnosis. We report cumulative survival probabilities 
Figure 1: Participating countries and regions (adults)
National registries in smaller countries are shown in boxes at diﬀ erent scales. 28 regional maps and a world map for childhood acute lymphoblastic leukaemia are in 
the appendix (pp 112–40).
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as percentages. For adults, we used the International 
Cancer Survival Standard (ICSS) weights, with age at 
diagnosis categorised into ﬁ ve groups: 15–44 years, 
45–54 years, 55–64 years, 65–74 years, and 75–99 years for 
eight solid tumours and leukaemia in adults; and 
15–54 years, 55–64 years, 65–74 years, 75–84 years, and 
85–99 years for prostate cancer.42 For children, we 
estimated survival for the age groups 0–4 years, 5–9 years, 
and 10–14 years; we obtained age-standardised estimates 
by assigning equal weights to the three age-speciﬁ c 
estimates.43 We derived CIs for both unstandardised and 
age-standardised survival estimates assuming a normal 
distribution, truncated to the range 0–100. We derived SEs 
with the Greenwood method44 to construct the CIs
We did not estimate survival if fewer than ten patients 
were available for analysis. If between ten and 49 patients 
were available for analysis in a given calendar period 
(1995–99, 2000–04, 2005–09), we merged data for 
two consecutive periods. For less common cancers in the 
smallest populations, we sometimes needed to merge data 
for all three periods. When between ten and 49 patients in 
total were available, we only estimated survival for all ages 
combined. If 50 or more patients were available, 
we attempted survival estimation for each age group. If an 
age-speciﬁ c estimate could not be obtained, we merged 
data for adjacent age groups and assigned the combined 
estimate to both age groups. If two or more age-speciﬁ c 
estimates could not be obtained, we present only the 
unstandardised estimate for all ages combined.
Role of the funding sources
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in 
the study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
279 cancer registries from 67 countries provided data for 
this study (ﬁ gure 1; appendix pp 112–40). Nine African 
countries took part (ten registries), eight countries were 
in Central and South America (27 registries), Canada and 
the USA comprised North America (57 registries), 
16 countries were in Asia (50 registries), 30 European 
countries participated (128 registries), and New Zealand 
and Australia represented Oceania (seven registries). For 
countries with less than 100% coverage of the population, 
the country name is used for brevity in the text (eg, Libya, 
the USA), but a more accurate term is used in the tables 
(eg, Libya [Benghazi], US registries). Some registries 
provided data for only part of their territory.
We examined records for 28 685 445 patients diagnosed 
with cancer of the stomach, colon, rectum, liver, lung, 
breast (women), cervix, ovary, and prostate in adults 
(age 15–99 years), leukaemia in adults, and precursor-cell 
acute lymphoblastic leukaemia in children (age 0–14 years) 
during the period 1995–2009 (table 2). Of these, 
1 682 081 (5·9%) records were for an in situ cancer, mostly 
of the cervix, breast, colon, or prostate. The proportions of 
in situ cancer are not comparable directly because some 
registries do not record in situ cancer, others did not 
submit data for index sites in which in situ malignant 
disease is common, and screening programmes in which 
in situ cancers are frequently detected were introduced in 
some countries during 1995–2009. The variation between 
continents is still of interest: for example, a little over 1% 
of cervical cancers in African registries were in situ, 
compared with 20% in Central and South American 
registries and 81% in Oceania. For breast cancer in situ, 
the variation was from 0·1% in African registries to 16% 
in North American registries and about 4–5% in other 
regions of the world (appendix pp 3–63). Patients with 
in situ cancer were not included in survival analyses.
We excluded a further 360 773 (1·3%) patients either 
because their year of birth, month or year of diagnosis, or 
year of last vital status were unknown, or because the 
tumour was not primary invasive malignant disease 
(behaviour code 3) or the morphology was that of Kaposi’s 
sarcoma or lymphoma in a solid organ, or for other 
reasons (table 2). The proportion of patients with an 
unknown date of last vital status ranged from 0% to 40% 
or more for some cancers in some African registries. 
Proportions are presented in the appendix (pp 3–63) for 
each registry, for all cancers combined, and for each 
cancer separately.
Of 26 642 591 patients eligible for inclusion in the 
survival analyses, 905 841 (3·4%) were excluded because 
their cancer was registered from a death certiﬁ cate only 
or discovered at autopsy (table 2), and 59 863 (0·2%) were 
excluded for other reasons, including deﬁ nite errors 
(eg, unknown vital status or sex, sex-site error, or invalid 
dates or sequence of dates) or possible errors (eg, apparent 
inconsistencies between age, cancer site, and morphology) 
for which the record was not later conﬁ rmed as correct by 
the relevant registry.
Of 25 676 887 patients available for survival analyses 
(96·4% of those eligible), pathological evidence of 
malignant disease (histological, cytological, or haema-
tological ﬁ ndings) was available for 23 338 015 patients 
for all cancers combined (91·1%; table 2), ranging from 
83·1% in Asian registries, 85·5% in African registries, 
and 87·4% in Central and South American registries to 
90–95% in Europe, Oceania, and North America. The 
range of pathological evidence at a national level was very 
wide, from 15% in The Gambia, 36% in Mongolia, and 
66% in Chinese registries, up to 99% or more in Belgium, 
Mauritius, and Sweden. For 938 703 (3·7%) patients, 
morphological features were poorly speciﬁ ed (eg, 
malignant neoplasm or tumour, ICD-O-3 codes 
8000–8005): this proportion also varied widely, from 
around 1% in North American registries to 17% for all 
African registries combined and as high as 59% in 
The Gambia. Data for every registry are shown in the 
appendix (pp 3–63).
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Calendar 
period
Patients 
submitted 
(n)
Ineligible patients¶ Eligible 
patients (n)
Exclusions|| Available for 
analysis (n)
Data quality indicators††
In situ 
(%)
Other 
(%)
DCO (%) Other (%) MV (%) Non-speciﬁ c 
morphology 
(%)
Lost to 
follow-
up (%)
Censored 
(%)
Africa 23 325 0·2% 39·5% 14 048 1·4% 9·6% 12 509 85·5% 17·0% 10·2% 28·8%
Algerian registries 1995–2009 6919 <0·1% 5·8% 6515 0·3% 17·4% 5358 93·8% 12·3% 0·0% 21·5%
Lesotho (childhood)† 1995–2009 22 0·0% 0·0% 22 0·0% 0·0% 22 100·0% 0·0% 0·0% 11·8%
Libya (Benghazi) 2003–2005 1698 0·0% 0·4% 1692 8·9% 0·5% 1533 84·4% 16·5% 0·0% 32·4%
Mali (Bamako) 1995–2009 1007 0·0% 78·3% 219 5·0% 2·3% 203 58·6% 41·4% 83·7% 6·4%
Mauritius* 2005–2005 855 0·0% 0·6% 850 0·0% 0·9% 842 100·0% 24·1% 0·0% NA
Nigeria (Ibadan) 1998–2007 2192 2·1% 60·1% 830 0·6% 3·6% 795 70·8% 0·0% 8·9% 65·1%
South Africa (Eastern Cape) 1998–2007 2404 0·0% 2·9% 2335 0·1% 4·4% 2230 70·5% 32·8% 45·7% 25·1%
The Gambia* 1995–1997 387 0·0% 10·1% 348 0·9% 10·3% 309 15·2% 58·9% 3·2% 14·2%
Tunisia (Central) 1995–2007 7841 0·1% 84·1% 1237 NA 1·6% 1217 99·1% 1·0% 0·7% 51·2%
America (Central and South) 467 456 3·0% 8·0% 416 140 13·7% 0·7% 356 173 87·4% 7·7% 0·1% 2·9%
Argentinian registries 1995–2009 40 482 5·0% 7·6% 35 377 11·1% 0·5% 31 244 97·9% 3·7% <0·1% 14·6%
Brazilian registries 1995–2009 119 423 5·4% 20·0% 89 067 9·5% 0·5% 80 113 92·8% 7·1% 0·2% 1·7%
Chilean registries 1998–2008 8920 8·2% 0·7% 8121 10·7% 0·5% 7213 90·3% 4·1% 0·5% 0·0%
Colombian registries 1995–2009 36 140 1·5% 5·7% 33 550 5·7% 0·8% 31 365 88·5% 12·0% <0·1% 19·5%
Cuba* 1998–2006 120 748 0·3% 2·1% 117 883 23·7% 0·3% 89 576 70·6% 11·7% 0·0% 0·0%
Ecuadorian registries 1995–2009 35 395 1·3% 5·7% 32 924 9·7% 4·3% 28 314 92·0% 3·7% 0·0% <0·1%
Puerto Rico* 2000–2009 81 886 3·9% 4·5% 74 937 6·7% 0·3% 69 745 97·2% 1·4% 0·0% 0·0%
Uruguay* 2002–2009 24 462 0·4% 0·3% 24 281 23·4% 0·0% 18 603 80·6% 20·9% 0·0% 0·0%
America (North) 12 233 257 6·0% 1·3% 11 340 569 1·8% 0·2% 11 109 332 94·8% 1·3% 0·8% <0·1%
Canada* 1995–2009 1 392 677 4·3% 0·6% 1 324 227 1·8% 0·5% 1 294 159 88·7% 1·5% 0·0% <0·1%
US registries 1995–2009 10 840 580 6·2% 1·4% 10 016 342 1·8% 0·2% 9 815 173 95·6% 1·3% 0·9% <0·1%
Asia 3 581 339 3·3% 0·9% 3 432 472 4·4% 0·2% 3 274 733 83·1% 11·4% 0·7% 2·6%
Chinese registries 1995–2009 241 044 0·1% 1·3% 237 656 1·6% <0·1% 233 736 66·4% 38·7% 3·5% 0·1%
Cyprus* 2004–2009 9986 2·8% 2·7% 9437 8·6% 0·2% 8609 98·7% 2·1% 0·0% 0·1%
Hong Kong* 1997–2006 6184 0·0% 0·0% 6184 0·0% 0·2% 6169 99·6% <0·1% 9·0% 8·5%
Indian registries 1995–2009 11 732 0·0% 1·5% 11 551 2·7% 0·1% 11 235 81·8% 9·7% 22·9% 9·9%
Indonesia (Jakarta) 2005–2007 3830 0·0% 18·1% 3138 1·3% 0·2% 3091 75·4% 23·0% 0·0% NA
Israel* 1995–2009 202 745 6·1% 2·0% 186 266 3·2% 0·2% 179 921 94·2% 6·4% 0·0% 0·0%
Japanese registries 1995–2009 1 065 707 3·7% 1·0% 1 015 315 13·3% <0·1% 879 341 86·4% 9·9% 0·0% 3·6%
Jordan* 2000–2009 19 191 0·0% 0·6% 19 081 <0·1% 0·9% 18 896 99·3% 1·5% 54·9% 0·0%
Korea*‡ 1995–2009 1 191 749 0·0% 0·8% 1 182 442 <0·1% 0·1% 1 180 925 82·5% 8·9% 0·0% 0·0%
Malaysia (Penang) 1995–2009 15 842 0·0% 2·5% 15 447 2·4% 1·8% 14 800 92·0% 9·8% 0·0% <0·1%
Mongolia* 2005–2009 13 415 1·8% 0·6% 13 096 <0·1% 4·5% 12 510 35·7% 1·2% 16·9% NA
Qatar* 2002–2009 780 0·8% 0·1% 773 2·7% 0·4% 749 90·0% 6·4% 0·0% 5·1%
Saudi Arabia* 1995–2008 24 216 1·4% 0·1% 23 876 2·6% 10·1% 20 860 95·2% 1·6% 0·0% 61·3%
Taiwan* 1995–2009 662 906 9·2% <0·1% 601 480 0·0% 0·1% 600 934 83·1% 9·6% 0·0% 0·0%
Thai registries 1995–2009 47 263 1·4% 0·7% 46 279 4·0% 0·1% 44 406 58·5% 38·4% 0·1% 23·4%
Turkey (Izmir) 1995–2009 64 749 3·3% 3·4% 60 451 3·0% 0·2% 58 551 92·9% 2·1% <0·1% 30·7%
Europe 11 449 869 6·5% 1·0% 10 584 050 4·5% 0·2% 10 086 145 89·7% 3·5% 0·3% 0·4%
Austria * 1995–2009 353 194 6·9% 0·6% 326 730 0·1% 0·9% 323 432 97·6% 2·5% 0·0% 0·0%
Belarus (childhood)† 1995–2009 726 0·0% 0·0% 726 0·0% 0·0% 726 99·9% 0·0% 2·8% 0·0%
Belgium* 2004–2009 256 073 8·7% 0·6% 232 152 <0·1% 0·2% 231 734 98·7% 1·5% 1·1% 0·0%
Bulgaria* 1995–2009 255 768 <0·1% 0·2% 255 158 11·2% <0·1% 226 566 81·4% 1·3% 0·1% 0·0%
Croatia* 1998–2009 148 131 0·0% 0·1% 148 031 6·0% <0·1% 139 147 84·9% 0·4% 0·0% 0·0%
Czech Republic* 1995–2009 469 330 6·4% 1·3% 433 523 7·9% 0·9% 395 462 90·8% 1·9% 0·0% 0·0%
Denmark* 1995–2009 251 533 0·0% 0·2% 250 931 0·4% 0·0% 249 943 93·2% 8·0% 0·1% 0·0%
Estonia* 1995–2008 51 544 1·4% 1·1% 50 283 3·8% 0·4% 48 193 89·0% 3·5% 0·4% 0·0%
(Table 2 continues on next page)
Articles
984 www.thelancet.com   Vol 385   March 14, 2015
Morphological conﬁ rmation for each cancer varied 
widely between continents and countries. Overall, 48·2% 
of liver cancers had morphological data available 
compared with 84·4% of lung cancers, at least 90% of 
other solid tumours and adult leukaemia, and 99% 
of childhood acute lymphoblastic leukaemia (appendix 
pp 3–63). Morphological conﬁ rmation was available for 
100% of acute lymphoblastic leukaemias in all the 
specialist childhood cancer registries, including the 
national registries in Lesotho and Belarus.
The 279 participating cancer registries represented 
an estimated total population of about 896 210 000 people 
in 2009, or 18·6% of the combined national popula-
tions of the 67 countries (4·8 billion total population; 
table 3); details by registry are provided in the appendix 
(pp 64–80). 100% coverage of the national population 
was provided by 40 countries. Population coverage in 
Australia  was 91%, and in the USA it was 83%. In the 
remaining 25 countries, population coverage ranged 
from 0·5% to 47%. In China, 21 participating registries 
covered 37·7 million people (2·8% of 1·35 billion total 
population), whereas the four registries in India covered 
5·9 million people (0·5% of 1·19 billion total population). 
China and India apart, data from 254 registries covered 
37% of the combined population of 2·3 billion people in 
65 countries.
Life expectancy at birth in 2009 varied widely between 
the 279 registry populations: for females, the range was 
46–87 years and for males it was 45–81 years (appendix, 
p 175). Life expectancy rose slightly from 1995 to 2009 
Calendar 
period
Patients 
submitted 
(n)
Ineligible patients¶ Eligible 
patients (n)
Exclusions|| Available for 
analysis (n)
Data quality indicators††
In situ 
(%)
Other 
(%)
DCO (%) Other (%) MV (%) Non-speciﬁ c 
morphology 
(%)
Lost to 
follow-
up (%)
Censored 
(%)
(Continued from previous page)
Finland* 1995–2009 235 156 6·5% 2·9% 213 137 2·3% <0·1% 208 129 96·1% 7·3% 0·1% 0·0%
French registries† 1995–2009 227 210 <0·1% 0·3% 226 622 <0·1% 0·2% 226 234 96·3% 2·6% 3·9% 4·1%
German registries 1995–2009 1 668 355 4·0% 1·2% 1 582 464 13·5% 0·1% 1 367 345 94·9% 1·0% 0·3% 0·1%
Gibraltar* 1999–2009 665 13·8% 15·8% 468 NA 1·3% 462 85·7% 0·9% 0·0% 2·2%
Iceland* 1995–2009 10 805 0·0% 0·8% 10 722 0·2% 0·0% 10 704 97·2% 2·8% 0·0% 0·0%
Ireland* 1995–2009 169 818 14·9% 1·4% 142 134 2·4% 0·1% 138 602 91·0% 1·1% 0·0% 0·0%
Italian registries 1995–2009 877 272 2·7% 0·5% 849 556 2·1% 0·2% 830 162 87·5% 12·5% 0·8% 1·0%
Latvia* 1995–2009 78 334 0·1% 0·2% 78 141 6·1% 0·5% 72 992 81·5% 0·5% 0·0% 0·0%
Lithuania* 1995–2009 132 425 2·8% 0·5% 127 999 3·6% 0·0% 123 380 84·9% 2·0% 1·0% 0·0%
Malta* 1995–2009 11 630 0·0% 0·9% 11 526 2·6% 0·5% 11 173 96·3% 7·9% 0·0% <0·1%
Netherlands* 1995–2009 716 617 2·9% 0·9% 688 714 0·3% 0·3% 684 601 97·0% 3·1% 0·5% 0·0%
Norway* 1995–2009 202 823 0·0% 0·4% 202 016 0·8% 0·0% 200 334 95·5% 4·7% 0·2% 0·0%
Poland* 1995–2009 813 485 1·2% 0·2% 802 179 4·1% 0·4% 766 183 79·6% 0·5% 0·1% 0·0%
Portugal* 1998–2009 240 114 2·8% 2·7% 226 878 0·2% 0·2% 225 902 95·9% 3·3% 0·1% 1·4%
Romania (Cluj) 2006–2009 6900 3·9% 0·7% 6583 18·0% 2·0% 5264 93·0% 0·8% 0·0% NA
Russia (Arkhangelsk) 2000–2009 23 609 0·0% <0·1% 23 602 3·3% 0·7% 22 643 82·4% 3·5% 1·1% 0·0%
Slovakia* 2000–2007 92 942 0·0% 0·3% 92 655 9·9% <0·1% 83 449 95·3% 5·5% 0·0% 0·0%
Slovenia* 1995–2009 95 466 14·8% 2·5% 78 973 2·7% <0·1% 76 835 94·5% 5·9% 0·1% 0·0%
Spanish registries 1995–2009 338 249 3·9% 2·4% 317 154 2·6% 0·3% 308 081 91·5% 5·4% 0·2% 0·8%
Sweden* 1995–2009 395 792 0·0% <0·1% 395 744 NA 0·0% 395 744 98·9% 2·1% 0·2% 0·0%
Swiss registries 1995–2009 151 879 6·9% 0·4% 140 737 1·7% 0·1% 138 125 95·2% 2·9% 3·2% 6·0%
UK* 1995–2009 3 174 024 14·5% 1·4% 2 668 512 3·5% 0·1% 2 574 598 83·3% 3·4% <0·1% 0·1%
Oceania 930 199 7·5% 0·6% 855 312 1·8% 0·2% 837 995 92·0% 4·2% 0·0% 4·1%
Australian registries 1995–2009 766 090 9·1% 0·7% 691 260 1·4% 0·2% 680 295 91·9% 3·4% 0·0% 5·0%
New Zealand* 1995–2009 164 109 0·0% <0·1% 164 052 3·3% 0·6% 157 700 92·6% 7·6% 0·0% 0·0%
Total 28 685 445 5·9% 1·3% 26 642 591 3·4% 0·2% 25 676 887 91·1% 3·7% 0·6% 0·7%
NA=not available. *100% coverage of the national population. †100% coverage of the national population for childhood leukaemia only. ‡South Korea. ¶In situ malignant disease (ICD-O-3 behaviour code 2): 
some registries do not register in situ cancers, other registries did not submit them. Other: records with incomplete data; or tumours that are benign (behaviour code 0), of uncertain behaviour (1), metastatic 
from another organ (6), or unknown if primary or metastatic (9); or patients falling outside the age range 0–14 years (children) or 15–99 years (adults); or other conditions. ||DCO=tumours registered from a 
death certiﬁ cate only or detected solely at autopsy. Other: vital status or sex unknown; or invalid sequence of dates; or inconsistency of sex-site, site-morphology, age-site, age-morphology, or 
age-site-morphology. †† MV=microscopically veriﬁ ed. Non-speciﬁ c morphology (solid tumours only): ICD-O-3 morphology code in the range 8000–8005. Censored: patients diagnosed during 1995–2004, with 
last known vital status “alive” but less than 5 years of follow-up. 
Table 2: Data quality indicators for patients diagnosed during 1995–2009, by continent and country (all cancers combined)
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Population covered¶ Stomach 
(n)
Colon 
(n)
Rectum 
(n)
Liver 
(n)
Lung 
(n)
Breast||
(n)
Cervix 
(n)
Ovary 
(n)
Prostate 
(n)
Leukaemia
(n)
Total
(n)
n % Adults Children
Africa
Total 15 983 791 5·8% 830 958 756 445 1833 3202 2357 346 1 085 592 105 12 509
Algerian 
registries
2 099 478 5·8% 551 406 343 177 908 1582 514 153 364 327 33 5358
Lesotho 
(childhood)†
756 000 100·0% ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 22 22
Libya 
(Benghazi)
1 582 160 26·5% 87 225 105 61 317 352 57 68 153 93 15 1533
Mali 
(Bamako)
902 723 13·4% ·· ·· ·· ·· ·· 203 ·· ·· ·· ·· ·· 203
Mauritius* 1 226 840 100·0% 65 81 65 23 84 290 93 52 58 31 ·· 842
Nigeria 
(Ibadan)
1 853 300 1·2% ·· 70 108 ·· ·· ·· 315 ·· 263 39 ·· 795
South Africa 
(Eastern 
Cape)
1 094 303 2·2% 54 40 38 98 216 372 1168 46 198 ·· ·· 2230
The Gambia* 1 628 330 100·0% 21 ·· ·· 85 21 33 149 ·· ·· ·· ·· 309
Tunisia 
(central)
4 840 657 46·1% 52 136 97 1 287 370 61 27 49 102 35 1217
America (Central and South)
Total 43 562 690 13·2% 24 610 43 552 10 405 4076 51 054 111 382 26 389 10 022 64 579 4960 5144 356 173
Argentinian 
registries†
5 123 973 12·8% 1742 4172 1308 14 2463 9886 2189 1076 4883 15 3496 31 244
Brazilian 
registries
11 012 413 5·7% 3689 3457 1681 672 4192 52 198 3209 1203 8292 1117 403 80 113
Chilean 
registries
931 477 5·5% 1333 614 270 181 878 1174 562 229 1653 257 62 7 213
Colombian 
registries
3 139 671 6·9% 4773 2439 ·· 741 3135 8346 3795 1352 6177 170 437 31 365
Cuba* 11 288 830 100·0% 5026 11 393 ·· ·· 25 654 18 757 10 726 3551 14 372 97 .. 89 576
Ecuadorian 
registries
4 987 086 33·8% 4821 1880 907 815 1698 5627 3957 1207 5333 1484 585 28 314
Puerto Rico* 3 718 810 100·0% 3226 11 930 3115 1653 5222 15 394 1951 1404 23 869 1820 161 69 745
Uruguay* 3 360 430 100·0% ·· 7667 3124 ·· 7812 ·· ·· ·· ·· ·· ·· 18 603
America (North)
Total 291 101 829 84·8% 289 269 1 533 456 428 293 201 342 2 532 324 2 493 295 175 743 302 513 2 689 226 432 639 31 232 11 109 332
Canada* 33 628 600 100·0% 43 996 194 803 49 333 21 124 305 723 286 173 20 651 25 874 289 868 53 175 3439 1 294 159
US registries 257 473 229 83·2% 245 273 1 338 653 378 960 180 218 2 226 601 2 207 122 155 092 276 639 2 399 358 379 464 27 793 9 815 173
Asia
Total 219 911 285 6·9% 680 012 405 348 229 351 465 575 594 333 414 619 139 621 71 388 194 319 70 615 9552 3 274 733
Chinese 
registries
37 688 165 2·8% 47 580 17 894 15 261 37 555 65 320 27 667 5251 5316 5597 6025 270 233 736
Cyprus* 819 100 100·0% 407 1330 375 104 1150 2482 150 265 1936 376 34 8609
Hong Kong* 3 707 500 100·0% ·· ·· ·· ·· ·· ·· 3792 2377 ·· ·· ·· 6169
Indian 
registries
5 877 408 0·5% 1942 147 138 242 1746 2691 2960 631 128 426 184 11 235
Indonesia 
(Jakarta)
9 607 787 4·0% 67 229 142 301 406 1004 459 235 137 97 14 3091
Israel* 7 273 800 100·0% 10 161 34 810 9595 2291 23 739 49 458 2887 5928 30 921 9339 792 179 921
Japanese 
registries
37 172 726 29·2% 230 800 139 071 63 269 81 085 154 292 97 409 17 249 17 221 65 114 12 784 1047 879 341
Jordan* 6 181 310 100·0% 1217 2653 1069 303 2 518 6674 373 691 1457 1451 490 18 896
Korea*‡ 48 164 970 100·0% 324 913 118 155 87 349 183 659 197 382 118 602 61 815 20 394 42 921 21 970 3 765 1 180 925
(Table 3 continues on next page)
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Population covered¶ Stomach 
(n)
Colon 
(n)
Rectum 
(n)
Liver 
(n)
Lung 
(n)
Breast|| 
(n)
Cervix 
(n)
Ovary 
(n)
Prostate 
(n)
Leukaemia
(n)
Total
(n)
n % Adults Children
(Continued from previous page)
Malaysia 
(Penang)
1 458 900 5·3% 1125 1931 1011 877 2784 3803 1227 719 740 424 159 14 800
Mongolia* 2 672 220 100·0% 2532 354 60 6358 1196 392 1178 264 39 113 24 12 510
Qatar* 1 564 080 100·0% 41 109 39 65 90 248 31 31 56 39 ·· 749
Saudi Arabia * 26 796 380 100·0% 1707 2515 1238 3165 2094 5179 734 954 1473 1801 ·· 20 860
Taiwan* 23 119 772 100·0% 51 506 78 146 45 212 133 440 111 317 82 264 35 308 13 036 36 455 12 239 2011 600 934
Thai registries 3 938 859 5·9% 1337 3198 1827 14 840 8382 5770 4722 1607 1120 1275 328 44 406
Turkey (Izmir) 3 868 308 5·4% 4677 4806 2766 1290 21 917 10 976 1485 1719 6225 2256 434 58 551
Europe
Total 301 311 488 46·5% 621 585 1 487 141 691 181 210 272 1 983 228 2 281 321 245 190 373 542 1 836 205 330 922 25 558 10 086 145
Austria* 8 371 710 100·0% 21 262 45 039 23 989 9368 51 467 70 149 7140 12 357 71 407 10 570 684 323 432
Belarus 
(childhood)†
1 387 671 100·0% ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 726 726
Belgium* 10 862 440 100·0% 8180 33 007 14 454 3050 43 212 57 203 3851 5783 55 141 7447 406 231 734
Bulgaria* 7 446 200 100·0% 21 072 31 599 20 332 5164 45 999 49 420 15 317 11 643 18 612 6859 549 226 566
Croatia* 4 349 930 100·0% 12 341 19 816 12 240 4063 33 037 26 912 4389 5885 14 885 5227 352 139 147
Czech 
Republic*
10 486 430 100·0% 24 175 73 556 31 175 8062 80 304 77 632 15 605 17 702 54 772 12 479 ·· 395 462
Denmark* 5 524 430 100·0% 8014 36 668 19 769 4035 56 379 59 135 6104 9328 41 162 8806 543 249 943
Estonia* 1 302 970 100·0% 6093 6159 3097 876 9975 8201 2317 2296 7060 2038 81 48 193
Finland* 5 343 930 100·0% 10 911 22 300 11 548 4129 30 317 54 675 2353 7714 57 012 6576 594 208 129
French 
registries†
11 563 608 18·4% 10 890 36 315 14 723 8996 30 470 52 334 3549 5835 47 893 9508 5721 226 234
German 
registries
36 511 217 43·9% 83 205 204 411 107 477 27 951 232 433 323 100 31 607 44 569 265 955 44 460 2177 1 367 345
Gibraltar* 29 253 100·0% 32 73 17 5 61 176 11 13 63 11 ·· 462
Iceland* 313 800 100·0% 532 1333 509 130 2053 2371 223 366 2813 346 28 10 704
Ireland* 4 410 420 100·0% 6952 20 706 8813 1564 25 042 31 160 3232 4933 30 060 5669 471 138 602
Italian 
registries
23 238 302 38·6% 67 401 139 202 40 810 42 965 153 997 181 654 10 400 23 787 135 881 32 057 2008 830 162
Latvia* 2 112 340 100·0% 9476 8380 5236 1376 15 713 13 617 3016 4533 8994 2555 96 72 992
Lithuania* 3 101 970 100·0% 14 672 11 677 8578 1944 22 425 19 047 7179 6392 26 047 5120 299 123 380
Malta* 422 870 100·0% 687 1693 722 141 1866 3238 160 549 1662 399 56 11 173
Netherlands* 16 561 280 100·0% 31 142 109 467 41 810 4788 144 869 176 885 10 292 21 021 120 745 22 549 1033 684 601
Norway* 4 835 630 100·0% 8765 33 809 15 840 1789 32 745 38 651 4573 7660 50 016 5962 524 200 334
Poland* 38 193 590 100·0% 60 115 93 762 60 178 15 018 225 554 151 046 39 367 39 430 79 083 2630 ·· 766 183
Portugal* 10 776 872 100·0% 25 315 39 016 18 641 3647 27 423 47 868 6861 4977 46 210 5530 414 225 902
Romania 
(Cluj)
677 942 3·1% 535 618 275 161 1028 1073 458 213 655 240 8 5264
Russia 
(Arkhangelsk)
1 246 204 0·9% 5006 2927 1840 225 5220 3654 1005 1078 1331 357 ·· 22 643
Slovakia* 5 425 040 100·0% 6767 16 002 7521 1295 15 545 15 859 4349 3564 8914 3407 226 83 449
Slovenia* 2 044 250 100·0% 6864 11 173 6409 1658 15 976 15 240 2827 2837 11 025 2673 153 76 835
Spanish 
registries
10 002 689 21·9% 22 326 54 275 18 868 12 105 58 048 57 242 5316 8948 58 421 11 541 991 308 081
Sweden* 9 310 300 100·0% 15 320 50 722 29 449 7543 46 744 90 168 6780 12 999 121 681 13 451 887 395 744
Swiss 
registries†
3 666 300 47·4% 5901 18 300 7457 4072 23 183 33 550 1924 4579 32 976 5514 669 138 125
UK* 61 791 900 100·0% 127 634 365 136 159 404 34 152 552 143 620 061 44 985 102 551 465 729 96 941 5862 2 574 598
(Table 3 continues on next page)
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in most populations, but in some countries it changed 
substantially between the earliest and latest years for 
which data were available, from a decline of 6–9 years 
in South Africa and Lesotho (attributable largely to 
HIV/AIDS),45 to an increase of 6 years or more in 
Estonia, Latvia (for males), and South Korea, and in 
some regions of Brazil (males), China, and Germany 
(males; data not shown).
Whenever possible, ﬁ ndings are presented for 
patients diagnosed during 1995–99, 2000–04, and 
2005–09, by continent, country, and registry (ﬁ gures 2 
to 4; appendix pp 3–173). When data were available for 
more than one registry in a given country, survival 
estimates were derived by pooling data for that country, 
excluding data from registries for which estimates were 
judged less reliable (ﬁ gures 2 and 3). Survival estimates 
were ﬂ agged as less reliable if a higher than usual 
proportion of patients was excluded from analyses 
because their cancer was registered from the death 
certiﬁ cate only, or had an unknown date for last vital 
status, or because not all deaths were ascertained. Less 
reliable estimates are not always outliers in the global 
distribution, but when they are, they have been omitted 
from this discussion. Less reliable estimates are also 
excluded from the distribution of survival among 
registries in each continent (ﬁ gure 4).
Data for stomach cancer are available for 
1 645 596 patients. 191 registries in 48 countries 
contributed data for 1995–99, 241 registries in 
56 countries provided data for 2000–04, and 
241 registries in 59 countries provided data for 2005–09 
(table 3; appendix pp 64–80). For patients diagnosed 
during 2005–09, age-standardised 5-year net survival 
for stomach cancer was very high in South Korea 
(58%), Japan (54%), and Mauritius (41%; table 4; 
appendix p 142). 5-year survival from stomach cancer 
was 30–39% in Austria, Belgium, China, Germany, 
Iceland, Italy, Portugal, Switzerland, and Taiwan. 
5-year survival in Denmark, Malta, Poland, and the UK 
was lower than in most other European countries 
(18–19%). Survival was less than 10% in Gibraltar and 
Libya, but those two estimates are based on fewer than 
100 cases (table 4; appendix pp 64–80). In most 
countries, survival from stomach cancer remained in 
the narrow range of 25–30% from 1995–99 to 2005–09. 
Very large increases were seen in South Korea (from 
33% to 58%) and China (from 15% to 31%), but survival 
rose by less than 10% in some countries on all 
continents (appendix p 153). Survival from stomach 
cancer fell by 6–17% in Brazil, Cyprus, Malaysia, 
Thailand, and Turkey, declines that were not seen for 
most other cancers in these registries. We could not 
assess survival trends for stomach cancer in African 
countries. The range of 5-year survival estimates for 
stomach cancer in 2005–09 varied widely between 
registries in Africa, Asia, and Central and South 
America (appendix p 164).
Data for colon cancer are available for 3 613 067 patients 
(table 3). 191 registries in 48 countries contributed data 
for 1995–99, 244 registries in 58 countries provided 
data for 2000–04, and 242 registries in 61 countries 
had data for 2005–09 (appendix pp 64–80). For patients 
diagnosed with colon cancer during 2005–09, 
age-standardised 5-year net survival was 50–59% in 
many countries, although it did surpass 60% in 
North America, Oceania, 12 European countries, and a 
few countries in Central and South America and Asia 
(table 4; appendix p 143). 5-year net survival from colon 
cancer was 40–49% in Argentina, Bulgaria, Chile, 
Colombia, Latvia, and Russia, and it was less than 40% 
in India, Indonesia, and Mongolia. In most countries, 
5-year survival from colon cancer increased from 
1995–99 to 2005–09, but it fell in Argentina and Cyprus 
(table 4; appendix p 154). Pooled 5-year survival estimates 
for Canada and the USA were already high (57% and 61%, 
respectively) for patients diagnosed with colon cancer in 
1995–99, but they increased to 63% and 65%, 
respectively, for individuals diagnosed during 2005–09. 
Data were generally available from the same registries 
throughout the period 1995–2009 in North America and 
Population covered¶ Stomach 
(n)
Colon 
(n)
Rectum 
(n)
Liver 
(n)
Lung 
(n)
Breast|| 
(n)
Cervix 
(n)
Ovary 
(n)
Prostate 
(n)
Leukaemia
(n)
Total
(n)
n % Adults Children
(Continued from previous page)
Oceania
Total 24 339 214 92·3% 29 290 142 612 53 875 12 739 131 489 183 109 12 925 21 491 213 853 33 860 2752 837 995
Australian 
registries
20 016 274 90·8% 23 821 114 778 44 152 10 583 108 025 148 633 10 219 16 899 173 796 27 162 2227 680 295
New Zealand* 4 322 940 100% 5469 27 834 9723 2156 23 464 34 476 2706 4592 40 057 6698 525 157 700
Worldwide
Total 896 210 297 18·6% 1 645 596 3 613 067 1 413 861 894 449 5 294 261 5 486 928 602 225 779 302 4 999 267 873 588 74 343 25 676 887
*100% coverage of the national population. †100% coverage of the national population for childhood leukaemia only. ‡South Korea. ¶Data are from the UN Population Division for 2009,40 national authorities 
in Canada, Portugal, and the UK, or the cancer registry. ||In female patients.
Table 3: Population coverage and number of patients diagnosed during 1995–2009, by continent and country
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Oceania, where survival from colon cancer was either 
stable or improving, and the range of estimates was 
narrow (appendix p 165). High outlier values for 
2005–09 are for Yukon (Canada; 78%, a merged estimate 
based on 109 cases) and Australian Capital Territory 
(Australia; 74%, based on 247 cases; appendix pp 64–111).
Data for rectal cancer are available for 1 413 861 patients 
(table 3). 188 registries in 46 countries provided data for 
1995–99, 240 registries in 57 countries had data available 
for 2000–04, and 238 registries in 60 countries 
contributed data for 2005–09 (appendix pp 64–80). 
For patients diagnosed with cancer of the rectum 
during 2005–09, age-standardised 5-year net survival 
was in the range 50–59% in many countries. Survival 
was very high (70% or more) in Cyprus, Iceland, and 
Qatar, and high (60–69%) in South Korea, 
North America, Oceania, and nine European countries 
(table 4; appendix p 144). Survival from rectal cancer 
was very low in India (29%). During 1995–2009, survival 
from rectal cancer increased in most countries, but it 
0 10 20 30 40 50 60 70 80 90 100
1995–99
Breast cancer (women)
5-year net survival (%)
0 10 20 30 40 50 60 70 80 90 100
2000–04
5-year net survival (%)
New Zealand*
Australia
Russia
Latvia*
Slovakia*
Lithuania*
Estonia*
Bulgaria*
Poland*
Romania
Malta*
Croatia*
Czech Republic*
Ireland*
Slovenia*
UK*
Denmark*
Austria*
Portugal*
Spain
Gibraltar*
Netherlands*
Germany
Iceland*
Belgium*
Switzerland
Norway*
Italy
Sweden*
Finland*
France
§Saudi Arabia*
§Jordan*
Mongolia*
India
Malaysia
Thailand
Indonesia
Turkey
China
Taiwan*
Korea*
Japan
Qatar*
Israel*
Cyprus*
Canada*
USA
Colombia
Argentina
Chile
Cuba*
Puerto Rico*
Ecuador
Brazil
§†Mali
The Gambia*
South Africa
§Algeria
§Tunisia
Libya
Mauritius*
0 10 20 30 40 50 60 70 80 90 100
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Iceland*
Belgium*
Switzerland
Norway*
Italy
Sweden*
Finland*
France
Saudi Arabia*
§Jordan*
Mongolia*
India
Malaysia
Thailand
Indonesia
Turkey
China
Taiwan*
Korea*
Japan
Qatar*
Israel*
Cyprus*
Canada*
USA
Colombia
Argentina
Chile
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Australia
Russia
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Slovakia*
Lithuania*
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Bulgaria*
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Malta*
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Czech Republic*
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Slovenia*
UK*
Denmark*
Austria*
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Spain
Gibraltar*
Netherlands*
Germany
Iceland*
Belgium*
Switzerland
Norway*
Italy
Sweden*
Finland*
France
§Saudi Arabia*
Jordan*
Mongolia*
India
Malaysia
Thailand
Indonesia
Turkey
China
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Japan
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Israel *
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Canada*
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Figure 2: Global distribution of age-standardised 5-year net survival for women diagnosed with breast cancer during 1995–99, 2000–04, and 2005–09, by continent and country
Age-standardised 5-year net survival estimates for other cancers are presented in the appendix (pp 141–51). Survival estimates for every country are ranked from highest to lowest within every 
continent; for ease of reference, the ranking for 2005–09 is used for 1995–99 and 2000–04. Error bars represent 95% CIs. Grey bars represent African countries; red bars represent America (Central and 
South); light green bars represent America (North); purple bars represent Asian countries; blue bars represent European countries; and dark green bars represent Oceania. *100% coverage of the national 
population. †National estimate not age-standardised. §National estimate ﬂ agged as less reliable because the only estimate or estimates available are from a registry or registries in this category.
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was stable or even falling in Argentina, Brazil, Chile, 
India (Karunagappally), Malaysia, and Uruguay 
(appendix p 155).
Data for liver cancer are available for 894 449 patients 
(table 3). 189 registries in 46 countries contributed data for 
1995–99, 236 registries in 54 countries provided data for 
2000–04, and 236 registries in 57 countries had data 
available for 2005–09 (appendix pp 64–80). However, 
international comparisons are more limited for liver 
cancer than for other malignant diseases because 
estimates from 20 countries were ﬂ agged as less reliable, 
mainly because of a high proportion of cancer registrations 
from a death certiﬁ cate only (appendix pp 24–28). 
Age-standardised 5-year net survival from liver cancer was 
generally low (10–20%) in most countries, both in the 
developed and developing world, throughout the period 
1995–2009 (table 4; appendix p 145). Survival only reached 
20% or more for patients diagnosed during 2005–09 in 
some east Asian countries (Japan, South Korea, and 
Taiwan), where a steady rise in survival from liver cancer 
has been seen since 1995–99. Even for 2005–09, survival 
was still very low (less than 10%) in Colombia, Denmark, 
Estonia, Finland, India, Malta, Mongolia, Norway, Russia, 
Slovenia, Thailand, and the UK. Estimates judged less 
reliable were mostly very similar to those that were robust. 
5-year survival from liver cancer increased between 
1995–99 and 2005–09 in the two countries in North 
America, four countries in Asia, and 13 European 
countries. Survival declined in Thailand from 16% to 8% 
(based on 14 800 cases). The high survival estimate for 
Mauritius (53%) is a national ﬁ gure, but it is based on only 
23 cases and is not age-standardised.
Data for lung cancer are available for 5 294 261 patients 
(table 3). 190 registries in 48 countries provided data for 
1995–99, 240 registries in 57 countries contributed data 
for 2000–04, and 240 registries in 60 countries had data 
available for 2005–09 (appendix pp 64–80). 
Age-standardised 5-year net survival from lung cancer 
was typically low, in the range 10–20% for most 
geographical areas, both in the developed and developing 
world (table 4, appendix pp 146 and 168). The general 
pattern is very similar to that of liver cancer. International 
variation in survival is less striking than for cancers with 
good prognosis, but diﬀ erences are still noticeable. 
Figure 3: Trends in age-standardised 5-year net survival for women diagnosed with breast cancer during 1995–99, 2000–04, and 2005–09, by continent or 
region and country
Trends in age-standardised 5-year net survival for other cancers are presented in the appendix (pp 152–62). Countries have been grouped into 12 geographical 
regions. ARG=Argentina. AUS=Australia. AUT=Austria. BEL=Belgium. BGR=Bulgaria. BRA=Brazil. CAN=Canada. CHE=Switzerland. CHL=Chile. CHN=China. 
COL=Colombia. CUB=Cuba. CYP=Cyprus. CZE=Czech Republic. DEU=Germany. DNK=Denmark. DZA=Algeria. ECU=Ecuador. ESP=Spain. EST=Estonia. FIN=Finland. 
FRA=France. GBR=United Kingdom. GIB=Gibraltar. GMB=The Gambia. HRV=Croatia. IDN=Indonesia. IND=India. IRL=Ireland. ISL=Iceland. ISR=Israel. ITA=Italy. 
JOR=Jordan. JPN=Japan. KOR=South Korea. LBY=Libya. LTU=Lithuania. LVA=Latvia. MLI=Mali. MLT=Malta. MNG=Mongolia. MUS=Mauritius. MYS=Malaysia. 
NLD=Netherlands. NOR=Norway. NZL=New Zealand. POL=Poland. PRI=Puerto Rico. PRT=Portugal. QAT=Qatar. ROU=Romania. RUS=Russia. SAU=Saudi Arabia. 
SVK=Slovakia. SVN=Slovenia. SWE=Sweden. TWN=Taiwan. THA=Thailand. TUN=Tunisia. TUR=Turkey. USA=United States of America. ZAF=South Africa. §Continent 
or region with one or more national estimates ﬂ agged as less reliable.
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For patients diagnosed during 2005–09, 5-year survival 
from lung cancer was higher than 20% in only three 
countries: Japan (30%), Israel (24%), and Mauritius 
(37%). The survival estimate for Mauritius is based on 
only 84 cases diagnosed in 2005 (appendix pp 64–80). 
Survival from lung cancer was very low (less than 10%) in 
Bulgaria, Lithuania, Mongolia, and Thailand, and only 
2% in Libya (Benghazi; based on 317 patients diagnosed 
during 2003–05). Between 1995–99 and 2005–09, survival 
from lung cancer rose by 7% in Israel and Japan, 
and it increased in China (from 8% to 18%), India 
(Karunagappally; from 4% to 10%; appendix pp 81–111) 
and South Korea (from 10% to 19%). Rises of 2–4% were 
noted in Colombia, North America, and Europe. Survival 
from lung cancer fell from 19% to 10% in Turkey (Izmir), 
but this reduction could be attributable to improvement 
in data quality. Smaller decreases (2–4%) were seen in 
Cyprus, Croatia, Malaysia, and Lithuania.
Data for breast cancer are available for 5 486 928 women 
(table 3). 193 registries in 49 countries provided data for 
1995–99, 245 registries in 57 countries had data available for 
2000–04, and 243 registries in 59 countries contributed data 
for 2005–09 (appendix pp 64–80). Most survival estimates 
were judged reliable. For women diagnosed during 
2005–09, age-standardised 5-year net survival from breast 
cancer was 80% or higher in 34 countries around the world 
(table 4, ﬁ gures 2 to 4). However, breast cancer survival was 
lower than 70% in Malaysia (68%) and India (60%) and very 
low in Mongolia (57%) and South Africa (53%). Between 
1995–99 and 2005–09, survival from breast cancer increased 
in Central and South America, particularly in Brazil (from 
78% to 87%), Colombia (from 66% to 76%), and Ecuador 
(from 69% to 83%; ﬁ gure 3). Survival also rose in Algeria 
(from 17% to 60%), but this trend is less reliable. We were 
unable to assess survival trends in most other African 
countries. The very low survival estimate for breast cancer 
in Mali (13·6%; Bamako) is not age-standardised and is a 
pooled estimate based on 203 women diagnosed during 
1995–2004. These women represent only a small proportion 
of all those registered with breast cancer in this period; for 
most women, obtaining information on their vital status 
proved impossible. In North America and Oceania, survival 
from breast cancer was high, with a fairly narrow range 
between registries (84–89%) and with stable or slightly 
improving survival seen up to 2005–09. Survival also rose 
in Europe but was generally lower than in North America 
and Oceania and with a much wider geographic range 
(ﬁ gure 4).
Data for cervical cancer are available for 602 225 women 
(table 3). 192 registries in 51 countries provided data for 
1995–99, 244 registries in 58 countries contributed data 
for 2000–04, and 244 registries in 61 countries provided 
data for 2005–09 (appendix pp 64–80). The global range 
in 5-year net survival from cervical cancer is very wide, 
particularly in Africa, Central and South America, and 
Asia (table 4; appendix p 169). For women diagnosed with 
cancer of the cervix during 2005–09, age-standardised 
5-year net survival was 70% or higher in Iceland, 
Mauritius, Norway, South Korea, and Taiwan; the 
estimate for Qatar is also above 70% but is based on 
only 16 cases and is not age-standardised (table 4; 
appendix p 147). In 34 of 61 countries around the world, 
Figure 4: Global range of age-standardised 5-year net survival estimates for women diagnosed with breast cancer in 228 cancer registries
Each box-plot shows the range of survival estimates among all those cancer registries for which suitable estimates could be obtained for patients diagnosed in a given 
calendar period in each continent. The number of registries included in each box-plot is shown in parentheses. Survival estimates considered less reliable are not 
included. The vertical line inside each box denotes the median survival value, and the box shows the IQR between the lower and upper quartiles. The extreme limits of 
the box-plot are 1·5 times the IQR below the lower quartile and above the upper quartile. Open circles indicate outlier values, outside this range. Data for other cancers 
are presented in the appendix (pp 163–73).
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Stomach Colon Rectum Liver Lung Breast Cervix Ovary Prostate Leukaemia
(adult)
ALL 
(children)
Africa
Algerian registries
1995–99 5·1§
(2·0–8·2)
10·8§
(7·9–13·6)
7·9§
(4·0–11·8)
·· 6·0§
(3·9–8·0)
17·1§
(13·8–20·3)
23·4§
(18·0–28·9)
13·9§
(7·9–19·9)
44·0§
(34·3–53·8)
21·2§
(10·1–32·4)
··
2000–04 17·6§
(11·6–23·7)
48·6§
(33·6–63·6)
41·2§
(32·5–49·8)
17·9§
(11·5–24·4)
8·2§
(4·6–11·9)
29·5§
(25·3–33·6)
59·5§
(51·5–67·5)
42·9§
(20·8–64·9)
55·5§
(50·6–60·3)
32·3§
(22·1–42·5)
··
2005–09 10·3§
(6·7–14·0)
57·2§
(45·6–68·9)
45·5§
(36·3–54·8)
17·5§
(11·7–23·4)
14·8§
(11·2–18·4)
59·8§
(48·6–71·1)
55·1§
(49·8–60·4)
41·8§
(22·2–61·4)
58·5§
(51·2–65·9)
13·6§
(6·7–20·5)
54·1§
(31·3–76·8)
Lesotho (childhood)†
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 39·5
(16·4–62·7)
Libya (Benghazi)
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 3·0
(0·0–7·6)
30·7
(21·0–40·5)
50·5
(33·2–67·9)
0·2§
(0·0–0·8)
2·2
(0·7–3·6)
76·6
(55·5–97·7)
39·4
(28·5–50·4)
22·1
(10·3–33·9)
41·4
(27·3–55·6)
6·2
(1·4–11·0)
70·1
(43·4–96·9)
Mali (Bamako)
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 ·· ·· ·· ·· ·· 13·6§
(0·0–30·1)
·· ·· ·· ·· ··
2005–09 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
Mauritius*
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 40·7
(24·3–57·0)
55·5
(41·0–70·1)
68·9
(48·6–89·2)
52·6
(28·9–76·3)
37·2
(24·4–50·0)
87·4
(78·1–96·7)
86·7
(77·9–95·6)
82·7
(63·8–100·0)
77·3
(61·0–93·5)
57·2
(37·4–76·9)
··
Nigeria (Ibadan)
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 ·· ·· ·· ·· ·· ·· 93·6§
(83·7–
100·0)
·· 97·4§
(89·5–100·0)
·· ··
2005–09 ·· 0·1§
(0·0–0·4)
46·0§
(18·4–73·6)
·· ·· ·· 96·0§
(90·4–
100·0)
·· 91·0§
(81·8–100·0)
82·7§
(59·8–100·0)
··
South Africa 
(Eastern Cape)
1995–99 ·· ·· ·· ·· ·· 71·5
(51·4–91·6)
37·0
(24·7–49·4)
·· ·· ·· ··
2000–04 ·· ·· ·· ·· ·· 37·9
(21·1–54·7)
63·0
(54·2–71·8)
·· 85·3§
(60·0–100·0)
·· ··
2005–09 ·· ·· ·· 10·2§
(0·0–22·9)
19·0§
(0·0–38·4)
53·4
(35·5–71·3)
54·9
(41·5–68·3)
90·9§
(67·8–100·0)
100·0§
(85·5–100·0)
·· ··
The Gambia* ·
1995–99 0·3§
(0·0–1·0)
·· ·· 4·5§
(0·2–8·8)
30·0§
(3·6–56·4)
11·9§
(0·0–24·7)
19·5§
(11·0–28·0)
·· ·· ·· ··
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
Tunisia (central)
1995–99 ·· ·· ·· ·· 6·9§
(0·9–12·9)
85·6§
(71·5–99·7)
·· ·· ·· ·· ··
2000–04 ·· ·· ·· ·· 15·0§
(4·3–25·7)
76·7§
(66·8–86·7)
·· ·· ·· ·· ··
2005–09 49·0§
(27·9–70·2)
67·6§
(57·4–77·8)
78·5§
(64·6–92·4)
·· 10·3§
(0·0–20·6)
68·4§
(64·5–72·2)
42·4§
(25·7–59·0)
47·8§
(25·2–70·5)
100·0§
(100·0–100·0)
26·5§
(15·0–37·9)
50·1§
(26·0–74·2)
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Argentinian 
registries†
1995–99 ·· ·· ·· ·· ·· ·· 45·9
(35·0–56·8)
·· ·· ·· ··
2000–04 19·2§
(14·9–23·6)
46·0§
(42·0–50·0)
44·4
(34·4–54·3)
·· 20·8§
(16·3–25·2)
75·5
(70·5–80·5)
52·0
(46·5–57·5)
26·8
(17·7–35·9)
85·0
(75·5–94·4)
·· 64·6
(62·2–67·0)
2005–09 16·0§
(12·9–19·2)
40·6§
(34·5–46·7)
31·0
(23·3–38·7)
24·2§
(1·6–46·7)
11·9§
(9·6–14·2)
76·6
(71·4–81·9)
50·6
(46·7–54·5)
29·7
(23·7–35·8)
86·6
(80·6–92·6)
90·0§
(68·0–100·0)
66·9
(64·4–69·3)
Brazilian registries
1995–99 33·1
(24·7–41·5)
55·9
(48·6–63·3)
54·7
(45·3–64·1)
15·9§
(7·1–24·7)
18·6
(11·2–26·0)
78·2
(73·5–82·8)
60·2
(55·0–65·4)
35·1
(26·0–44·3)
83·4
(78·7–88·2)
34·3§
(16·2–52·4)
71·9
(58·9–84·8)
2000–04 28·2
(24·2–32·2)
58·1
(54·2–62·0)
52·8
(46·6–59·1)
17·9§
(12·3–23·6)
13·7
(9·4–18·0)
86·9
(84·3–89·5)
67·5
(64·0–71·0)
41·3
(34·6–48·1)
93·0
(90·5–95·5)
30·1§
(16·3–43·9)
68·7
(60·5–77·0)
2005–09 24·9
(21·2–28·6)
58·2
(54·4–61·9)
55·9
(50·2–61·7)
11·6§
(7·5–15·7)
18·0
(12·8–23·2)
87·4
(84·8–90·0)
61·1
(57·4–64·9)
31·8
(25·5–38·2)
96·1
(93·9–98·4)
20·3§
(11·0–29·7)
65·8
(57·7–74·0)
Chilean registries
1995–99 13·4§
(7·7–19·1)
39·0
(24·5–53·6)
·· ·· ·· 73·3
(58·2–88·5)
41·9
(30·9–53·0)
·· 69·7
(58·3–81·2)
·· ··
2000–04 16·4
(12·7–20·1)
36·4
(28·3–44·5)
41·7
(32·2–51·2)
4·5§
(1·4–7·6)
6·2
(2·4–10·0)
76·8
(69·7–84·0)
55·5
(49·1–61·9)
29·6
(20·1–39·2)
81·2
(75·0–87·5)
10·3
(4·8–15·8)
··
2005–09 18·0
(14·3–21·7)
43·3
(34·9–51·7)
37·7
(27·9–47·5)
7·9§
(2·0–13·8)
6·3
(2·2–10·4)
77·1
(70·4–83·8)
50·9
(44·3–57·5)
32·2
(19·2–45·1)
88·7
(83·5–93·8)
16·1
(8·4–23·9)
66·4
(51·3–81·5)
Colombian registries
1995–99 15·4
(13·1–17·8)
29·2
(24·8–33·7)
·· 3·7
(0·0–7·7)
6·1
(4·2–8·0)
65·7
(61·0–70·3)
50·6
(46·8–54·5)
27·3
(20·5–34·1)
67·1
(63·1–71·1)
·· 40·9
(31·5–50·3)
2000–04 17·7
(15·2–20·2)
42·3
(37·9–46·7)
·· 4·3
(1·4–7·3)
9·0
(6·8–11·2)
70·4
(67·0–73·9)
56·8
(53·3–60·2)
33·0
(27·0–39·0)
80·5
(77·6–83·4)
19·6
(7·8–31·4)
49·3
(40·1–58·4)
2005–09 16·6
(13·9–19·2)
43·3
(38·8–47·9)
·· 5·3
(2·2–8·5)
9·0
(6·6–11·4)
76·1
(72·2–80·0)
59·3
(55·4–63·2)
31·1
(25·4–36·8)
78·6
(75·4–81·8)
20·1
(8·2–32·0)
53·8
(43·9–63·6)
Cuba*
1995–99 26·2§
(23·2–29·2)
45·8§
(43·2–48·3)
·· ·· 21·8§
(20·5–23·2)
72·8
(70·1–75·5)
66·4
(63·2–69·6)
35·4
(30·7–40·0)
54·5§
(51·5–57·6)
·· ··
2000–04 23·8§
(22·0–25·6)
44·1§
(42·7–45·6)
·· ·· 14·1§
(13·4–14·8)
73·3
(71·9–74·8)
61·9
(60·2–63·7)
34·7
(31·9–37·5)
47·6§
(45·8–49·3)
·· ··
2005–09 26·2§
(23·1–29·3)
46·4§
(44·0–48·8)
·· ·· 18·2§
(17·0–19·4)
77·7
(75·4–79·9)
64·0
(61·2–66·7)
39·8
(35·5–44·2)
56·1§
(53·2–59·0)
59·6
(46·6–72·7)
··
Ecuadorian registries
1995–99 40·1§
(34·9–45·4)
61·5
(52·1–71·0)
45·5
(34·6–56·5)
16·2§
(9·2–23·2)
34·5§
(22·2–46·9)
68·9
(62·9–74·9)
59·7
(54·5–65·0)
35·2
(27·3–43·1)
76·3
(70·7–81·9)
29·5
(22·3–36·7)
63·6
(53·4–73·8)
2000–04 28·5§
(25·7–31·3)
69·9
(58·4–81·5)
48·3
(38·6–58·0)
15·3§
(10·0–20·5)
37·8§
(26·9–48·7)
79·6
(74·5–84·6)
58·5
(53·7–63·3)
44·7
(35·2–54·2)
90·9
(86·5–95·3)
36·0
(28·1–44·0)
64·2
(54·9–73·6)
2005–09 31·9§
(29·1–34·6)
68·2
(57·7–78·7)
52·6
(44·3–61·0)
17·7§
(12·3–23·2)
28·7§
(22·0–35·4)
83·2
(79·2–87·2)
61·7
(56·8–66·5)
47·0
(37·1–57·0)
92·4
(88·7–96·0)
33·5
(26·3–40·7)
62·6
(53·7–71·6)
Puerto Rico*
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 26·8
(24·3–29·3)
60·3
(58·7–61·9)
54·3
(51·2–57·3)
12·2§
(9·4–15·0)
14·8§
(13·2–16·4)
82·6
(81·1–84·1)
60·9
(57·2–64·6)
34·5
(30·5–38·6)
97·5
(96·5–98·5)
34·1
(30·0–38·2)
78·8
(69·8–87·7)
2005–09 28·6
(26·0–31·2)
60·9
(59·4–62·3)
57·8
(54·7–60·8)
9·2§
(7·1–11·2)
15·8§
(14·2–17·4)
83·0
(81·6–84·5)
59·3
(55·7–62·9)
34·8
(30·8–38·8)
97·7
(96·8–98·6)
30·2
(26·9–33·5)
80·1
(71·1–89·0)
Uruguay*
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 ·· 56·5§
(54·1–59·0)
53·0
(49·0–57·1)
·· 12·5§
(10·9–14·0)
·· ·· ·· ·· ·· ··
2005–09 ·· 53·4§
(50·5–56·3)
49·4
(45·6–53·2)
·· 9·1§
(7·9–10·3)
·· ·· ·· ·· ·· ··
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Canada*
1995–99 21·1
(20·4–21·9)
56·8
(56·3–57·3)
56·5
(55·4–57·5)
12·1
(11·2–13·1)
15·1
(14·8–15·3)
83·7
(83·3–84·1)
66·2
(64·8–67·5)
36·5
(35·3–37·7)
87·5
(87·1–87·9)
46·8
(45·9–47·8)
85·8
(83·4–88·2)
2000–04 23·1
(22·3–23·9)
60·1
(59·6–60·6)
60·5
(59·6–61·5)
15·4
(14·5–16·4)
15·6
(15·4–15·9)
85·3
(84·9–85·7)
67·5
(66·1–68·8)
35·5
(34·4–36·6)
91·0
(90·7–91·4)
52·4
(51·5–53·2)
91·0
(89·0–92·9)
2005–09 24·8
(24·0–25·6)
62·8
(62·4–63·3)
62·8
(61·9–63·7)
17·7
(16·8–18·7)
17·3
(17·1–17·6)
85·8
(85·5–86·2)
66·8
(65·4–68·1)
37·5
(36·3–38·6)
91·7
(91·4–92·0)
55·2
(54·4–56·0)
90·6
(88·6–92·7)
US registries
1995–99 22·1
(21·8–22·5)
60·5
(60·3–60·7)
60·0
(59·6–60·4)
8·5
(8·2–8·8)
15·2
(15·1–15·3)
86·0
(85·8–86·1)
64·2
(63·6–64·7)
38·9
(38·5–39·2)
93·2
(93·0–93·3)
44·5
(44·2–44·9)
83·1
(82·1–84·0)
2000–04 25·8
(25·5–26·2)
63·7
(63·5–63·9)
63·1
(62·7–63·4)
11·9
(11·7–12·2)
16·6
(16·5–16·7)
87·9
(87·8–88·1)
63·6
(63·1–64·1)
39·6
(39·3–40·0)
96·4
(96·3–96·5)
48·8
(48·5–49·1)
86·6
(85·8–87·4)
2005–09 29·1
(28·7–29·4)
64·7
(64·5–64·9)
64·0
(63·6–64·3)
15·2
(14·9–15·5)
18·7
(18·6–18·8)
88·6
(88·5–88·7)
62·8
(62·3–63·3)
40·9
(40·5–41·2)
97·2
(97·0–97·3)
51·8
(51·5–52·1)
87·7
(86·9–88·4)
Asia
Chinese registries
1995–99 15·3
(12·2–18·3)
33·5
(28·3–38·8)
28·9
(23·9–33·9)
2·4
(1·6–3·2)
7·5
(5·7–9·3)
53·8
(44·3–63·2)
40·1
(30·0–50·2)
41·0
(26·9–55·1)
62·9
(45·2–80·6)
4·7
(1·9–7·5)
10·9
(1·5–20·2)
2000–04 29·0
(28·1–29·9)
51·2
(49·4–53·0)
48·0
(46·2–49·9)
10·9
(10·2–11·7)
18·1
(17·5–18·8)
78·0
(75·5–80·5)
56·1
(52·0–60·1)
42·6
(38·3–47·0)
55·8
(50·5–61·1)
18·2
(15·7–20·8)
50·0
(39·7–60·2)
2005–09 31·3
(30·4–32·1)
54·6
(53·1–56·0)
53·2
(51·6–54·9)
12·5
(11·8–13·3)
17·5
(16·9–18·0)
80·9
(79·1–82·7)
59·9
(57·2–62·7)
38·9
(36·4–41·3)
63·8
(59·6–68·1)
21·2
(19·1–23·4)
61·1
(51·3–70·8)
Cyprus*
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 42·9
(28·8–57·0)
68·4
(60·5–76·3)
·· ·· 18·4
(12·3–24·5)
88·7
(80·9–96·5)
·· ·· ·· ·· ··
2005–09 26·3
(19·9–32·6)
58·1
(48·7–67·4)
70·2
(61·0–79·3)
9·8§
(2·4–17·1)
15·4
(12·2–18·6)
90·6
(85·6–95·5)
64·5
(55·6–73·5)
43·2
(34·3–52·2)
93·1
(89·0–97·2)
61·3
(53·4–69·2)
83·2
(69·7–96·7)
Hong Kong*
1995–99 ·· ·· ·· ·· ·· ·· 68·7
(65·8–71·7)
47·0
(41·0–53·0)
·· ·· ··
2000–04 ·· ·· ·· ·· ·· ·· 72·1
(69·9–74·3)
53·3
(48·8–57·9)
·· ·· ··
2005–09 ·· ·· ·· ·· ·· ·· 69·4
(65·9–72·9)
52·9
(45·8–60·0)
·· ·· ··
Indian registries
1995–99 21·2
(6·1–36·2)
·· ·· ·· 4·4
(1·9–6·9)
48·1
(37·2–58·9)
49·1
(39·4–58·9)
23·2§
(8·8–37·7)
·· 7·3§
(0·9–13·7)
··
2000–04 9·3
(4·2–14·4)
33·2
(23·0–43·4)
40·7
(24·5–57·0)
1·8
(0·0–4·0)
9·8
(3·8–15·8)
55·3
(42·2–68·5)
47·4
(36·0–58·9)
·· 35·7
(20·0–51·4)
·· ··
2005–09 18·7
(9·3–28·2)
37·3
(26·7–48·0)
29·4
(17·5–41·3)
4·3
(0·0–9·4)
9·6
(4·7–14·5)
60·4
(46·5–74·3)
45·8
(34·9–56·7)
13·9§
(6·8–21·0)
58·1
(38·3–77·8)
6·0§
(0·3–11·6)
64·7
(50·1–79·2)
Indonesia (Jakarta)
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 18·4
(0·0–40·5)
28·1
(18·8–37·3)
58·0
(38·3–77·8)
19·9
(4·3–35·5)
12·2§
(1·1–23·3)
77·7
(65·3–90·2)
65·1§
(55·8–74·3)
39·9§
(27·0–52·8)
43·5
(1·1–85·9)
39·8
(20·1–59·4)
44·3
(13·4–75·3)
Israel*
1995–99 26·5
(24·8–28·3)
60·0
(58·8–61·2)
56·8
(54·6–59·0)
8·2§
(6·0–10·4)
17·3
(16·3–18·3)
80·9
(79·8–81·9)
62·5
(58·7–66·2)
38·9
(36·3–41·4)
85·0
(83·4–86·6)
43·7
(41·5–45·9)
82·3
(76·5–88·1)
2000–04 29·3
(27·5–31·0)
66·2
(65·1–67·3)
62·5
(60·5–64·6)
14·7§
(11·9–17·6)
20·7
(19·7–21·7)
85·5
(84·5–86·5)
65·8
(62·4–69·2)
40·5
(38·2–42·8)
91·9
(90·8–93·0)
54·5
(52·4–56·7)
84·7
(80·0–89·5)
2005–09 28·6
(26·9–30·3)
69·4
(68·3–70·4)
66·6
(64·5–68·6)
14·2§
(11·6–16·7)
23·8
(22·8–24·9)
86·7
(85·8–87·7)
65·9
(62·6–69·3)
42·0
(39·7–44·4)
94·0
(93·0–95·0)
50·4
(48·4–52·4)
85·0
(80·5–89·4)
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Japanese registries
1995–99 51·7
(51·2–52·2)
61·4
(60·7–62·1)
56·6
(55·5–57·6)
21·4
(19·5–23·3)
22·9
(21·5–24·3)
81·8
(80·8–82·9)
65·7
(64·1–67·3)
26·3
(24·2–28·4)
65·7
(63·4–67·9)
12·1
(10·0–14·2)
77·5
(72·4–82·6)
2000–04 53·6
(53·2–54·1)
62·2
(61·6–62·7)
57·8
(57·0–58·7)
26·4
(24·3–28·5)
28·5
(27·5–29·5)
84·2
(83·5–84·8)
65·1
(63·9–66·4)
33·1
(31·3–34·8)
83·4
(82·4–84·5)
17·9
(16·5–19·4)
77·8
(72·8–82·8)
2005–09 54·0
(53·6–54·5)
64·4
(63·9–64·9)
60·3
(59·6–61·1)
27·0
(25·5–28·4)
30·1
(29·1–31·0)
84·7
(84·1–85·3)
66·3
(65·2–67·5)
37·3
(35·6–38·9)
86·8
(86·0–87·7)
18·9
(17·6–20·3)
81·1
(76·8–85·4)
Jordan*
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 48·2§
(31·7–64·8)
53·0§
(40·1–65·8)
26·3§
(11·8–40·9)
22·9§
(5·2–40·6)
7·7§
(4·3–11·2)
57·6§
(46·4–68·8)
17·1§
(3·1–31·0)
17·2§
(6·9–27·5)
35·5§
(23·8–47·2)
6·9§
(0·0–15·8)
15·1§
(6·4–23·8)
2005–09 28·8§
(14·6–43·0)
48·1§
(35·0–61·3)
21·4§
(9·6–33·2)
17·1§
(3·2–31·1)
4·4§
(2·0–6·8)
43·1§
(31·2–55·0)
10·3§
(0·0–21·8)
8·0§
(2·9–13·2)
27·4§
(16·3–38·5)
7·1§
(0·0–16·3)
16·4§
(6·8–26·0)
Korea*‡
1995–99 32·8
(32·5–33·1)
42·5
(41·9–43·1)
51·6
(50·5–52·8)
10·8
(10·4–11·3)
9·6
(9·4–9·9)
76·7
(74·4–78·9)
73·7
(72·8–74·6)
42·1
(39·6–44·6)
63·7
(61·5–65·9)
15·4
(13·9–17·0)
62·9
(60·1–65·7)
2000–04 41·0
(40·8–41·3)
60·4
(59·8–61·1)
60·8
(60·0–61·5)
15·2
(14·9–15·6)
15·2
(14·9–15·5)
79·6
(78·1–81·0)
70·0
(69·5–70·6)
43·3
(41·5–45·1)
75·8
(74·4–77·3)
18·8
(17·6–20·0)
72·8
(70·3–75·4)
2005–09 57·9
(57·5–58·2)
66·0
(65·4–66·6)
65·9
(65·2–66·6)
20·1
(19·8–20·5)
18·5
(18·2–18·8)
82·7
(81·4–84·0)
77·1
(76·4–77·8)
44·2
(42·6–45·8)
82·2
(81·1–83·3)
23·4
(22·2–24·6)
77·1
(74·7–79·5)
Malaysia (Penang)
1995–99 34·3
(27·9–40·7)
52·4
(46·1–58·7)
48·3
(38·4–58·2)
10·3
(5·7–14·9)
15·1
(12·1–18·0)
64·8
(56·8–72·9)
54·6
(48·6–60·5)
44·7
(30·0–59·3)
62·4
(52·0–72·8)
16·0
(3·6–28·4)
77·3
(65·5–89·2)
2000–04 26·5
(20·9–32·1)
47·9
(42·7–53·1)
38·7
(32·1–45·2)
19·2
(12·1–26·3)
13·1
(10·6–15·6)
71·1
(64·3–78·0)
58·4
(53·0–63·7)
42·5
(30·3–54·6)
57·8
(48·3–67·3)
25·2
(13·4–37·1)
68·7
(56·5–81·0)
2005–09 24·2
(19·6–28·8)
53·3
(48·7–57·9)
42·5
(36·3–48·7)
13·3
(9·3–17·4)
10·7
(8·6–12·7)
67·8
(62·4–73·3)
55·2
(50·2–60·2)
42·9
(33·6–52·1)
66·4
(57·8–74·9)
12·1
(7·4–16·9)
69·4
(57·4–81·5)
Mongolia*
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 15·1
(12·6–17·6)
30·6
(22·5–38·8)
15·9
(0·9–30·8)
8·5
(6·9–10·0)
6·6
(4·1–9·1)
56·5
(46·1–66·8)
59·5
(53·3–65·8)
52·1
(39·7–64·5)
39·6
(17·2–61·9)
35·6
(23·7–47·5)
34·3
(11·9–56·8)
Qatar*
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 27·3
(11·8–42·7)
68·2
(48·2–88·1)
77·8
(58·3–97·3)
4·1
(0·0–10·3)
13·2
(3·2–23·2)
85·3
(66·8–
100·0)
85·5
(71·6–99·3)
37·2
(10·1–64·2)
55·3 
(47·2–63·4)
52·8
(29·6–76·0)
··
Saudi Arabia*
1995–99 33·6§
(20·8–46·3)
43·3§
(31·9–54·7)
61·0§
(8·3–100·0)
23·5§
(15·5–31·5)
21·3§
(8·5–34·1)
70·9§
(56·6–85·3)
62·2§
(50·6–73·8)
49·4§
(31·6–67·3)
64·8§
(53·9–75·8)
61·4§
(47·1–75·7)
··
2000–04 44·1§
(31·8–56·3)
49·0§
(37·8–60·2)
59·3§
(7·3– 100·0)
16·0§
(10·8–21·2)
12·9§
(7·3–18·5)
78·4§
(68·3–88·5)
65·6§
(56·8–74·4)
53·0§
(38·2–67·9)
65·3§
(55·8–74·8)
50·9§
(41·4–60·4)
··
2005–09 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
Taiwan*
1995–99 36·1
(35·2–37·0)
56·2
(55·2–57·1)
56·2
(55·0–57·4)
17·1
(16·6–17·6)
13·3
(12·8–13·8)
77·2
(75·4–79·0)
75·4
(74·5–76·3)
44·2
(41·0–47·4)
69·7
(67·5–71·9)
24·3
(22·3–26·3)
63·4
(59·4–67·3)
2000–04 35·8
(35·0–36·6)
57·1
(56·3–57·8)
58·1
(57·1–59·1)
19·5
(19·1–19·9)
11·6
(11·3–12·0)
80·7
(79·4–82·1)
74·5
(73·6–75·4)
44·3
(42·0–46·6)
76·0
(74·3–77·7)
22·3
(20·7–23·9)
71·8
(68·1–75·5)
2005–09 36·4
(35·5–37·2)
59·5
(58·8–60·2)
60·5
(59·5–61·4)
22·2
(21·8–22·6)
14·3
(13·9–14·7)
82·4
(81·1–83·6)
74·0
(73·0–75·0)
45·6
(43·5–47·8)
77·9
(76·5–79·3)
22·9
(21·4–24·3)
77·9
(74·5–81·3)
Thai registries
1995–99 18·5
(9·7–27·4)
43·7
(34·0–53·4)
34·9
(22·7–47·1)
15·6
(12·0–19·2)
31·9
(20·2–43·6)
65·9
(50·3–81·6)
55·0
(48·8–61·3)
55·7
(36·1–75·4)
51·3
(30·8–71·7)
9·7
(3·4–16·0)
51·2
(39·5–62·9)
2000–04 15·3
(11·1–19·6)
52·2
(47·4–57·1)
35·7
(30·2–41·2)
10·5
(9·2–11·8)
9·7
(8·3–11·2)
72·9
(63·7–82·0)
57·7
(54·4–61·0)
47·3
(37·4–57·1)
64·7
(56·4–72·9)
17·2
(12·2–22·3)
58·9
(49·2–68·6)
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2005–09 12·4
(9·0–15·8)
50·4
(46·2–54·6)
39·7
(34·7–44·6)
7·8
(6·7–8·8)
8·1
(7·0–9·2)
71·3
(65·8–76·8)
55·9
(52·7–59·1)
41·1
(33·2–49·0)
57·7
(50·7–64·7)
13·5
(9·5–17·5)
55·1
(45·5–64·6)
Turkey (Izmir)
1995–99 32·5
(25·8–39·1)
54·3
(48·3–60·4)
47·5
(40·4–54·6)
11·8
(6·5–17·1)
19·2
(15·7–22·7)
72·8
(67·6–78·0)
59·2
(51·0–67·5)
40·7
(32·6–48·8)
77·4
(69·3–85·5)
31·5
(23·0–40·1)
63·7
(54·2–73·3)
2000–04 20·0
(16·8–23·2)
50·4
(46·8–54·0)
46·8
(42·4–51·2)
19·2
(14·2–24·1)
11·0
(9·7–12·3)
81·5
(78·4–84·5)
63·4
(58·4–68·5)
46·0
(38·1–54·0)
80·2
(76·0–84·4)
36·4
(30·3–42·5)
69·1
(60·9–77·2)
2005–09 17·1
(14·9–19·2)
52·9
(49·9–55·9)
45·3
(41·5–49·0)
14·2
(10·4–18·0)
10·1
(9·1–11·0)
78·6
(76·0–81·2)
60·9
(56·3–65·4)
39·0
(33·3–44·8)
80·6
(77·6–83·6)
33·1
(28·8–37·4)
73·1
(66·1–80·2)
Europe
Austria*
1995–99 29·5
(28·3–30·7)
57·1
(56·0–58·1)
54·8
(53·5–56·2)
8·7
(7·5–10·0)
14·1
(13·5–14·7)
78·7
(77·8–79·5)
62·3
(60·3–64·4)
42·2
(40·7–43·8)
84·7
(83·8–85·6)
39·8
(37·7–41·9)
85·9
(80·6–91·2)
2000–04 30·0
(28·7–31·3)
60·2
(59·3–61·2)
59·8
(58·5–61·1)
11·0
(9·8–12·2)
15·6
(15·0–16·3)
81·4
(80·6–82·2)
65·4
(63·3–67·4)
40·4
(38·9–42·0)
89·8
(89·1–90·5)
43·3
(41·5–45·1)
89·8
(85·3–94·2)
2005–09 33·1
(31·7–34·5)
63·0
(62·1–64·0)
62·1
(60·8–63·4)
12·9
(11·6–14·3)
17·9
(17·3–18·6)
82·9
(82·1–83·7)
66·0
(63·8–68·2)
41·6
(40·0–43·2)
90·5
(89·8–91·2)
45·8
(44·1–47·6)
91·1
(86·9–95·2)
Belarus (childhood)†
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 74·7
(69·4–79·9)
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 78·4
(72·9–83·9)
2005–09 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 88·3
(83·6–93·0)
Belgium*
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 27·9
(25·1–30·8)
64·0
(62·3–65·6)
62·3
(59·8–64·8)
19·9
(15·5–24·4)
15·3
(14·3–16·3)
84·8
(83·5–86·1)
66·0
(62·0–70·0)
42·5
(39·3–45·7)
92·0
(90·7–93·3)
57·5
(54·2–60·7)
80·2
(69·8–90·6)
2005–09 33·4
(31·9–34·8)
64·6
(63·8–65·4)
64·7
(63·5–66·0)
19·6
(17·7–21·6)
16·6
(16·1–17·2)
85·4
(84·7–86·0)
65·2
(63·1–67·2)
43·0
(41·2–44·7)
92·6
(91·9–93·2)
59·4
(57·7–61·0)
89·7
(86·1–93·3)
Bulgaria*
1995–99 11·2§
(10·2–12·2)
39·5
(38·0–41·0)
31·0
(29·4–32·6)
4·7§
(3·3–6·0)
5·9
(5·2–6·6)
68·0
(66·5–69·5)
46·7
(44·9–48·5)
27·7
(25·7–29·8)
45·2
(42·5–47·8)
21·2
(19·0–23·4)
58·0
(50·5–65·5)
2000–04 11·1§
(10·2–11·9)
43·8
(42·6–45·0)
36·9
(35·5–38·3)
3·8§
(2·7–4·8)
5·7
(5·0–6·4)
71·2
(70·0–72·5)
49·4
(47·8–51·0)
32·9
(30·9–34·9)
49·7
(47·3–52·0)
24·1
(21·9–26·2)
63·3
(55·4–71·2)
2005–09 12·9§
(12·0–13·8)
47·0
(45·8–48·2)
40·8
(39·3–42·3)
5·0§
(3·8–6·3)
6·3
(5·6–7·1)
73·9
(72·7–75·1)
53·0
(51·4–54·6)
35·4
(33·5–37·2)
53·4
(51·1–55·8)
25·0
(22·9–27·1)
71·0
(64·2–77·7)
Croatia*
1995–99 24·0
(21·7–26·3)
50·1
(47·6–52·7)
44·6
(41·5–47·6)
13·2§
(9·8–16·5)
16·5
(15·1–17·9)
77·5
(75·0–79·9)
68·1
(64·2–72·1)
37·5
(32·9–42·2)
61·4
(56·8–66·0)
38·6
(34·3–42·8)
··
2000–04 21·6
(20·3–22·9)
49·8
(48·4–51·2)
46·5
(44·8–48·3)
11·6§
(9·8–13·4)
15·2
(14·5–16·0)
75·1
(73·7–76·4)
65·6
(63·0–68·3)
39·1
(36·7–41·4)
67·7
(65·5–69·9)
37·2
(34·8–39·6)
77·6
(70·8–84·4)
2005–09 21·3
(20·0–22·6)
52·0
(50·7–53·3)
48·2
(46·5–49·9)
12·2§
(10·4–14·0)
13·6
(12·9–14·3)
77·9
(76·6–79·3)
65·3
(62·7–68·0)
36·8
(34·6–39·1)
75·1
(73·2–77·1)
37·6
(35·3–39·9)
85·9
(80·0–91·8)
Czech Republic*
1995–99 16·6
(15·7–17·6)
45·3
(44·4–46·1)
38·6
(37·4–39·9)
4·7§
(3·7–5·7)
8·5§
(8·1–9·0)
72·7
(71·7–73·7)
61·3
(59·8–62·7)
32·6
(31·1–34·0)
64·6
(63·0–66·1)
42·8
(40·8–44·9)
··
2000–04 21·8
(20·7–22·9)
51·4
(50·6–52·2)
46·9
(45·7–48·1)
5·5§
(4·4–6·5)
10·9
(10·4–11·4)
77·8
(77·0–78·6)
62·2
(60·7–63·8)
34·5
(33·2–35·9)
75·6
(74·4–76·9)
46·8
(45·0–48·6)
··
2005–09 23·2
(22·0–24·3)
54·9
(54·1–55·7)
50·3
(49·1–51·5)
7·2§
(6·0–8·4)
12·3
(11·8–12·9)
80·0
(79·2–80·8)
64·5
(63·0–66·1)
36·6
(35·3–38·0)
83·1
(82·1–84·1)
46·1
(44·3–47·8)
··
Denmark*
1995–99 13·8
(12·3–15·3)
48·2
(47·1–49·4)
47·6
(46·0–49·2)
2·6
(1·6–3·5)
8·0
(7·5–8·5)
75·8
(74·8–76·8)
63·1
(60·9–65·4)
31·2
(29·5–33·0)
46·4
(44·5–48·3)
45·4
(43·2–47·5)
85·6
(79·4–91·8)
2000–04 15·3
(13·7–16·9)
52·1
(50·9–53·2)
53·8
(52·2–55·3)
4·4
(3·1–5·7)
9·6
(9·1–10·1)
80·7
(79·8–81·6)
63·2
(60·8–65·6)
33·2
(31·5–34·9)
64·0
(62·5–65·5)
51·2
(49·1–53·3)
84·5
(78·9–90·1)
2005–09 17·9
(16·2–19·5)
55·9
(54·8–57·0)
58·4
(56·9–59·8)
6·1
(4·4–7·7)
11·3
(10·7–11·9)
82·0
(81·1–82·9)
64·8
(62·3–67·2)
37·3
(35·4–39·2)
77·2
(75·9–78·5)
56·8
(54·6–59·0)
87·2
(81·5–92·9)
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Estonia*
1995–99 20·0
(18·2–21·9)
49·7
(46·8–52·6)
37·7
(34·0–41·3)
5·4
(2·8–7·9)
8·2
(7·0–9·5)
62·3
(59·3–65·2)
58·2
(54·4–62·1)
28·2
(25·0–31·3)
55·9
(51·3–60·6)
37·4
(32·9–42·0)
··
2000–04 22·3
(20·3–24·4)
48·8
(46·1–51·5)
46·5
(43·0–50·1)
5·6
(2·8–8·3)
10·9
(9·6–12·3)
70·4
(67·8–73·0)
62·9
(59·0–66·8)
31·3
(27·9–34·8)
67·1
(63·7–70·4)
43·5
(39·2–47·8)
··
2005–09 22·8
(20·5–25·2)
51·7
(48·7–54·6)
48·9
(44·9–52·9)
8·7
(5·1–12·3)
11·9
(10·3–13·5)
72·4
(69·6–75·2)
66·7
(62·6–70·8)
38·7
(34·6–42·8)
73·2
(69·9–76·5)
38·4
(34·1–42·7)
62·6
(52·0–73·3)
Finland*
1995–99 27·0
(25·4–28·6)
58·7
(57·2–60·2)
54·6
(52·5–56·7)
6·9
(5·1–8·8)
11·0
(10·2–11·7)
82·8
(81·7–83·9)
66·2
(62·6–69·8)
39·1
(36·8–41·4)
79·3
(77·9–80·6)
45·1
(42·5–47·7)
82·4
(76·3–88·4)
2000–04 25·9
(24·3–27·6)
61·2
(59·8–62·6)
59·8
(57·9–61·8)
7·2
(5·5–8·8)
11·8
(11·0–12·6)
86·5
(85·5–87·4)
68·1
(64·6–71·6)
40·9
(39·0–42·8)
90·0
(89·1–90·9)
47·6
(45·3–50·0)
84·7
(78·0–91·4)
2005–09 25·2
(23·5–26·9)
62·9
(61·5–64·3)
62·9
(61·1–64·8)
7·9
(6·2–9·6)
12·3
(11·5–13·2)
86·8
(85·9–87·7)
65·3
(61·7–69·0)
44·9
(42·9–46·9)
93·2
(92·3–94·0)
50·7
(48·4–52·9)
81·9
(75·3–88·5)
French registries†
1995–99 25·7
(24·2–27·2)
57·2
(56·1–58·2)
54·4
(52·8–56·0)
11·1
(9·8–12·5)
12·8
(12·2–13·5)
83·7
(82·9–84·6)
66·3
(63·9–68·8)
33·5
(31·6–35·4)
79·4
(78·1–80·7)
54·6
(52·6–56·6)
82·9
(81·0–84·8)
2000–04 27·3
(25·8–28·8)
59·7
(58·6–60·7)
57·0
(55·4–58·6)
13·5
(12·3–14·8)
13·9
(13·3–14·5)
86·5
(85·7–87·3)
60·5
(57·7–63·3)
39·8
(37·7–41·9)
89·4
(88·6–90·2)
58·9
(57·2–60·6)
88·4
(86·8–90·0)
2005–09 27·7
(25·3–30·2)
59·8
(58·2–61·4)
56·8
(54·5–59·1)
14·4
(12·6–16·2)
13·6
(12·7–14·6)
86·9
(85·7–88·0)
58·9
(53·9–63·8)
39·0
(35·9–42·2)
90·5
(89·4–91·6)
59·2
(56·6–61·8)
89·2
(87·7–90·8)
German registries
1995–99 22·8
(21·5–24·2)
48·7
(47·5–49·9)
51·9
(50·7–53·1)
6·5
(4·8–8·2)
11·6
(11·0–12·2)
81·2
(80·6–81·8)
64·7
(63·3–66·0)
37·7
(36·2–39·1)
77·1
(75·6–78·5)
42·9
(40·9–44·9)
86·7
(83·5–89·9)
2000–04 30·0
(29·2–30·7)
62·1
(61·6–62·7)
60·2
(59·6–60·9)
10·5
(9·0–12·0)
15·1
(14·7–15·4)
84·1
(83·7–84·4)
64·8
(63·7–65·9)
39·9
(38·9–41·0)
89·3
(88·7–89·8)
50·1
(48·9–51·3)
87·3
(84·6–89·9)
2005–09 31·6
(30·8–32·3)
64·6
(64·1–65·1)
62·1
(61·5–62·7)
14·4
(12·9–16·0)
16·2
(15·8–16·5)
85·3
(84·9–85·6)
64·9
(63·9–65·9)
39·7
(38·7–40·7)
91·2
(90·7–91·6)
53·6
(52·5–54·6)
91·8
(89·8–93·7)
Gibraltar*
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 ·· ·· ·· ·· ·· 82·4
(70·3–94·4)
·· ·· ·· ·· ··
2005–09 9·4
(0·0–22·0)
57·9
(43·8–71·9)
57·8
(27·0–88·6)
·· 20·2
(7·2–33·3)
84·4
(73·4–95·5)
63·0
(23·8–
100·0)
59·3
(25·7–92·9)
67·4
(54·0–80·7)
44·0
(7·0–81·1)
··
Iceland*
1995–99 23·9
(17·4–30·4)
54·1
(47·9–60·2)
51·7
(42·8–60·7)
·· 14·3
(11·4–17·2)
83·0
(77·9–88·1)
63·6
(51·0–76·2)
30·4
(21·1–39·6)
74·8
(68·7–80·8)
39·1
(30·2–48·0)
··
2000–04 34·2
(26·1–42·3)
60·8
(54·9–66·8)
72·2
(63·8–80·7)
1·6
(0·0–3·7)
14·5
(11·5–17·4)
88·1
(83·5–92·8)
70·7
(61·8–79·6)
34·1
(26·9–41·4)
79·5
(74·8–84·1)
56·6
(45·6–67·6)
··
2005–09 32·3
(24·3–40·3)
65·1
(59·6–70·6)
76·5
(68·3–84·6)
11·0
(4·8–17·1)
15·0
(11·9–18·2)
85·3
(80·7–89·9)
73·1
(61·8–84·3)
38·6
(30·0–47·2)
83·5
(79·4–87·5)
54·4
(43·1–65·7)
84·1
(70·0–98·3)
Ireland*
1995–99 17·6
(15·7–19·4)
50·8
(49·2–52·4)
48·1
(45·6–50·5)
6·8
(3·8–9·8)
9·5
(8·6–10·3)
73·1
(71·5–74·7)
58·9
(54·5–63·3)
28·1
(25·7–30·6)
69·8
(67·8–71·8)
47·3
(44·2–50·4)
79·8
(72·9–86·7)
2000–04 18·7
(16·9–20·6)
53·6
(52·1–55·1)
51·5
(49·4–53·7)
11·8
(8·9–14·7)
10·3
(9·4–11·1)
77·7
(76·4–79·1)
58·1
(54·4–61·9)
29·6
(27·3–32·0)
84·2
(83·0–85·4)
54·9
(52·2–57·6)
83·1
(76·9–89·4)
2005–09 22·7
(20·7–24·7)
58·6
(57·2–60·0)
56·1
(53·9–58·3)
12·8
(10·0–15·6)
12·9
(12·0–13·8)
80·0
(78·7–81·3)
55·9
(52·6–59·3)
32·2
(29·8–34·6)
88·4
(87·3–89·5)
56·4
(53·9–59·0)
85·3
(79·1–91·5)
Italian registries
1995–99 31·1
(30·4–31·8)
57·5
(56·9–58·1)
53·3
(52·3–54·4)
11·5
(10·8–12·2)
12·9
(12·6–13·3)
82·8
(82·3–83·3)
64·4
(62·8–66·1)
36·1
(35·0–37·2)
79·1
(78·2–80·0)
47·0
(45·8–48·1)
82·8
(79·7–85·9)
2000–04 32·0
(31·3–32·6)
60·1
(59·6–60·6)
56·7
(55·8–57·6)
15·5
(14·8–16·2)
14·0
(13·7–14·4)
85·5
(85·1–85·9)
67·1
(65·6–68·6)
37·9
(36·9–38·9)
88·6
(88·1–89·1)
47·3
(46·3–48·3)
83·0
(79·9–86·1)
2005–09 32·4
(31·7–33·2)
63·2
(62·7–63·7)
59·5
(58·5–60·4)
17·9
(17·2–18·7)
14·7
(14·3–15·0)
86·2
(85·7–86·6)
68·3
(66·7–69·9)
39·2
(38·1–40·3)
89·7
(89·2–90·2)
46·7
(45·6–47·7)
87·7
(84·9–90·5)
(Table 4 continues on next page)
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Stomach Colon Rectum Liver Lung Breast Cervix Ovary Prostate Leukaemia
(adult)
ALL 
(children)
(Continued from previous page)
Latvia*
1995–99 21·3
(19·7–22·9)
40·9
(38·5–43·3)
34·1
(31·1–37·0)
7·2§
(4·4–9·9)
12·1
(10·8–13·3)
64·1
(61·7–66·6)
52·9
(49·2–56·6)
30·6
(28·0–33·2)
51·9
(47·8–56·0)
44·6
(40·4–48·9)
··
2000–04 20·7
(19·0–22·5)
42·4
(40·1–44·8)
36·4
(33·6–39·2)
7·2§
(4·3–10·0)
13·8
(12·6–15·1)
69·8
(67·5–72·1)
51·7
(48·0–55·4)
35·7
(32·9–38·6)
65·3
(62·2–68·5)
43·1
(38·9–47·2)
··
2005–09 22·8
(21·0–24·6)
45·3
(43·0–47·7)
38·6
(35·6–41·5)
6·4§
(4·0–8·8)
16·2
(14·9–17·6)
71·1
(68·9–73·4)
55·4
(51·9–59·0)
35·6
(32·9–38·4)
73·9
(71·0–76·8)
54·5
(49·5–59·4)
75·0
(64·3–85·8)
Lithuania*
1995–99 24·4
(22·7–26·1)
48·0
(45·2–50·7)
40·3
(37·4–43·2)
5·4§
(2·3–8·4)
10·0
(8·7–11·3)
65·3
(62·6–68·0)
53·2
(50·5–55·9)
33·2
(29·7–36·8)
51·8
(48·5–55·2)
36·6
(33·6–39·7)
59·5
(49·4–69·6)
2000–04 25·6
(24·0–27·2)
51·6
(49·4–53·9)
44·7
(42·2–47·2)
9·5§
(6·2–12·9)
8·3
(7·4–9·2)
70·3
(68·3–72·3)
57·0
(54·5–59·5)
33·0
(30·5–35·6)
81·2
(79·0–83·4)
39·5
(36·8–42·2)
72·6
(63·5–81·7)
2005–09 26·0
(24·3–27·7)
51·5
(49·4–53·7)
48·3
(45·8–50·9)
11·3§
(7·3–15·2)
7·7
(6·8–8·7)
72·1
(70·2–74·1)
61·3
(58·8–63·8)
35·8
(33·1–38·6)
92·4
(90·6–94·1)
44·7
(41·9–47·4)
69·6
(59·1–80·1)
Malta*
1995–99 17·5
(11·9–23·1)
49·3
(43·1–55·4)
49·8
(40·9–58·8)
·· 10·9
(8·0–13·8)
71·3
(67·1–75·5)
58·8
(44·7–72·9)
34·2
(25·9–42·6)
68·6
(61·0–76·1)
38·6
(30·7–46·4)
..
2000–04 15·5
(10·7–20·2)
57·6
(52·4–62·7)
51·4
(43·9–59·0)
10·8
(4·5–17·1)
9·3
(6·3–12·3)
76·3
(72·4–80·2)
52·8
(37·9–67·6)
37·9
(30·2–45·5)
82·7
(76·9–88·6)
24·2
(16·8–31·7)
..
2005–09 18·0
(12·8–23·2)
56·0
(51·2–60·8)
48·1
(41·0–55·2)
9·5
(6·5–12·4)
10·8
(8·0–13·6)
76·3
(72·7–79·9)
63·1
(49·3–76·9)
33·1
(27·2–39·0)
84·8
(79·9–89·7)
19·0
(12·8–25·3)
72·5
(59·5–85·4)
Nether lands*
1995–99 19·0
(18·1–19·8)
55·4
(54·7–56·1)
55·5
(54·3–56·6)
8·2
(6·7–9·8)
12·4
(12·1–12·8)
80·0
(79·4–80·6)
63·9
(62·0–65·7)
38·7
(37·5–39·9)
77·4
(76·5–78·3)
46·9
(45·4–48·3)
..
2000–04 19·5
(18·6–20·4)
57·7
(57·0–58·3)
57·7
(56·7–58·8)
9·7
(8·2–11·3)
12·2
(11·9–12·6)
83·5
(83·0–84·1)
65·7
(63·8–67·6)
37·3
(36·0–38·5)
82·7
(82·0–83·4)
48·4
(47·1–49·8)
84·5
(80·8–88·1)
2005–09 21·4
(20·5–22·4)
60·1
(59·5–60·7)
62·0
(61·0–63·0)
12·6
(10·8–14·3)
14·8
(14·4–15·1)
85·0
(84·5–85·5)
66·5
(64·6–68·4)
38·1
(36·8–39·3)
85·8
(85·2–86·4)
51·8
(50·5–53·1)
85·9
(82·7–89·2)
Norway*
1995–99 21·1
(19·4–22·9)
55·9
(54·6–57·2)
57·8
(56·1–59·5)
5·6
(3·4–7·8)
10·7
(10·0–11·5)
81·5
(80·3–82·6)
66·7
(64·1–69·4)
36·7
(34·7–38·8)
73·8
(72·5–75·1)
44·6
(41·9–47·3)
79·1
(71·4–86·8)
2000–04 22·0
(20·2–23·9)
58·4
(57·2–59·6)
61·7
(60·1–63·3)
7·4
(5·1–9·7)
11·7
(10·9–12·4)
84·1
(83·0–85·1)
70·6
(67·8–73·5)
40·2
(38·2–42·3)
82·4
(81·4–83·5)
48·9
(46·3–51·5)
87·7
(82·3–93·1)
2005–09 24·1
(22·1–26·1)
61·8
(60·6–62·9)
64·6
(63·0–66·2)
9·5
(6·9–12·2)
15·0
(14·1–15·8)
85·9
(84·9–87·0)
71·4
(68·6–74·3)
40·3
(38·3–42·4)
86·3
(85·4–87·2)
53·6
(51·0–56·2)
89·7
(84·4–94·9)
Poland*
1995–99 14·2
(13·2–15·1)
40·0
(38·7–41·3)
36·7
(35·3–38·2)
7·9§
(6·5–9·3)
11·4
(10·9–11·9)
66·9
(65·4–68·3)
50·0
(48·4–51·5)
30·6
(28·8–32·4)
54·3
(52·1–56·5)
44·1
(38·9–49·4)
..
2000–04 15·7
(15·1–16·2)
45·7
(45·1–46·4)
42·8
(42·0–43·5)
9·2§
(8·4–10·1)
11·7
(11·4–12·0)
72·3
(71·6–72·9)
51·7
(50·9–52·6)
32·8
(31·9–33·7)
68·5
(67·6–69·4)
44·5
(40·4–48·5)
..
2005–09 18·6
(18·0–19·2)
50·1
(49·5–50·7)
46·9
(46·1–47·6)
10·4§
(9·5–11·3)
13·4
(13·1–13·7)
74·1
(73·5–74·7)
53·0
(52·1–53·9)
34·3
(33·5–35·2)
74·1
(73·4–74·9)
49·0
(45·2–52·7)
..
Portugal*
1995–99 26·6
(24·5–28·7)
48·8
(46·7–50·9)
46·0
(43·2–48·8)
7·7
(4·7–10·7)
10·4
(9·1–11·7)
74·9
(72·8–76·9)
54·0
(50·0–58·0)
33·9
(29·8–38·1)
81·3
(79·2–83·4)
40·0
(35·3–44·7)
66·5
(51·5–81·4)
2000–04 29·7
(28·8–30·6)
56·3
(55·4–57·3)
54·2
(52·9–55·5)
13·4
(11·5–15·2)
10·4
(9·8–11·0)
81·4
(80·5–82·4)
60·3
(58·4–62·1)
39·4
(37·2–41·7)
87·2
(86·2–88·1)
41·2
(38·9–43·5)
80·6
(74·7–86·5)
2005–09 32·6
(31·6–33·5)
60·3
(59·4–61·2)
58·2
(57·0–59·5)
15·6
(13·6–17·5)
12·8
(12·1–13·4)
83·4
(82·5–84·3)
61·5
(59·7–63·2)
40·6
(38·4–42·9)
89·4
(88·5–90·2)
43·6
(41·3–45·8)
86·8
(80·7–92·9)
Romania (Cluj)
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2005–09 22·1§
(17·6–26·5)
58·4§
(52·1–64·7)
46·8
(38·7–55·0)
2·3§
(0·3–4·4)
16·2§
(13·5–19·0)
75·0
(69·1–80·9)
69·1
(63·1–75·1)
40·5§
(30·9–50·1)
79·5
(72·7–86·4)
41·2
(32·7–49·8)
··
(Table 4 continues on next page)
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5-year survival was in the range 60–69%. In general, 
cervical cancer survival was 50% or higher in all other 
countries, except for Libya (Benghazi, 39%) and India 
(Karunagappally, 46%). Survival estimates for northeast 
India (Guwahati, 32%; Sikkim, 53%) are ﬂ agged as less 
reliable because up to 30% of women could not be traced 
despite active follow-up (appendix pp 39–43). Survival for 
cervical cancer is stable or has increased slightly in most 
countries (appendix p 158). For example, in Central and 
South America, survival was stable at around 60% in 
Brazil, Cuba, Ecuador, and Puerto Rico. In the 10 years 
between 1995–99 and 2005–09, 5-year net survival 
increased from 42% to 51% in Chile and from 46% to 
51% in Argentina. In France, the decline in survival 
Stomach Colon Rectum Liver Lung Breast Cervix Ovary Prostate Leukaemia
(adult)
ALL 
(children)
(Continued from previous page)
Russia (Arkhan gelsk)
1995–99 ·· ·· ·· ·· .. .. .. .. .. ·· ··
2000–04 21·8
(19·2–24·4)
35·5
(32·3–38·8)
27·8
(23·8–31·7)
7·4
(3·1–11·8)
14·7
(12·6–16·9)
62·4
(58·1–66·6)
56·6
(51·1–62·2)
37·2
(31·2–43·2)
63·9
(54·9–73·0)
34·1
(25·6–42·6)
··
2005–09 19·9
(17·5–22·3)
40·6
(37·3–43·8)
30·4
(26·2–34·5)
9·4
(4·3–14·5)
15·7
(13·6–17·9)
70·6
(66·4–74·9)
54·9
(49·1–60·6)
40·4
(34·2–46·6)
69·6
(62·1–77·2)
42·0
(31·9–52·2)
··
Slovakia*
1995–99 ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· ··
2000–04 20·2
(18·8–21·6)
49·7
(48·5–51·0)
43·4
(41·6–45·2)
5·1§
(3·4–6·8)
9·6§
(8·9–10·4)
74·0
(72·5–75·6)
61·6
(59·2–64·0)
34·8
(32·3–37·4)
62·6
(60·3–64·9)
41·1
(38·3–43·8)
78·9
(71·6–86·2)
2005–09 19·7
(17·9–21·4)
49·9
(48·3–51·5)
44·0
(41·6–46·3)
5·3§
(3·1–7·4)
10·7§
(9·7–11·7)
72·1
(70·3–73·9)
58·8
(56·0–61·6)
33·9
(30·9–36·9)
66·0
(63·2–68·8)
37·2
(34·1–40·3)
78·2
(69·5–87·0)
Slovenia*
1995–99 20·1
(18·3–22·0)
45·1
(42·9–47·3)
40·5
(37·7–43·3)
3·0
(1·4–4·6)
8·5
(7·6–9·4)
71·3
(69·2–73·5)
62·9
(59·5–66·4)
33·4
(29·8–36·9)
61·1
(57·7–64·4)
44·3
(39·8–48·8)
83·1
(72·5–93·8)
2000–04 25·6
(23·6–27·7)
53·1
(51·2–55·1)
48·4
(45·9–50·9)
3·8
(2·2–5·3)
9·7
(8·9–10·6)
78·3
(76·5–80·2)
67·3
(63·8–70·7)
37·8
(34·4–41·2)
72·7
(70·2–75·3)
39·9
(36·2–43·6)
86·1
(74·5–97·6)
2005–09 26·7
(24·6–28·8)
56·0
(53·9–58·0)
55·2
(52·7–57·7)
5·2
(3·3–7·0)
11·4
(10·4–12·3)
80·2
(78·5–82·0)
68·9
(65·4–72·5)
37·5
(34·4–40·6)
78·1
(76·1–80·2)
37·9
(34·4–41·4)
75·7
(63·8–87·6)
Spanish registries†
1995–99 25·1
(24·0–26·2)
52·0
(51·1–53·0)
49·0
(47·4–50·5)
10·2
(9·0–11·4)
10·2
(9·7–10·7)
77·8
(76·8–78·7)
61·7
(59·4–64·0)
35·3
(33·4–37·1)
73·7
(72·3–75·0)
48·5
(46·5–50·5)
73·8
(68·3–79·3)
2000–04 25·3
(24·2–26·4)
56·1
(55·2–56·9)
55·2
(53·8–56·6)
14·3
(13·1–15·4)
11·5
(11·0–12·0)
82·2
(81·3–83·0)
63·4
(61·1–65·7)
38·1
(36·2–39·9)
84·6
(83·8–85·5)
50·7
(48·9–52·5)
81·5
(76·9–86·1)
2005–09 27·3
(26·1–28·5)
59·3
(58·4–60·1)
57·6
(56·2–59·0)
15·8
(14·6–17·1)
12·6
(12·1–13·1)
83·7
(82·8–84·5)
65·2
(62·9–67·6)
38·4
(36·6–40·2)
87·1
(86·3–87·9)
52·0
(50·2–53·9)
83·3
(79·1–87·4)
Sweden*
1995–99 21·2
(19·9–22·5)
55·4
(54·4–56·5)
57·9
(56·6–59·2)
5·3
(4·3–6·4)
12·2
(11·6–12·9)
83·8
(83·1–84·5)
65·0
(62·9–67·1)
40·8
(39·2–42·4)
75·4
(74·5–76·2)
48·5
(46·8–50·3)
85·0
(80·5–89·5)
2000–04 21·0
(19·6–22·3)
59·4
(58·5–60·4)
59·6
(58·4–60·8)
6·8
(5·6–8·0)
13·3
(12·7–14·0)
85·6
(84·9–86·3)
66·6
(64·4–68·8)
42·8
(41·2–44·4)
86·1
(85·5–86·7)
55·0
(53·3–56·7)
86·8
(82·6–90·9)
2005–09 23·2
(21·7–24·6)
62·5
(61·6–63·5)
62·0
(60·9–63·2)
11·1
(9·5–12·7)
15·6
(14·9–16·4)
86·2
(85·5–86·9)
67·8
(65·6–70·0)
43·5
(41·9–45·1)
89·2
(88·7–89·8)
59·2
(57·5–60·8)
85·5
(80·9–90·1)
Swiss registries†
1995–99 23·6
(21·4–25·8)
54·5
(52·8–56·3)
53·8
(51·2–56·4)
9·0
(7·0–11·1)
13·0
(12·1–13·9)
78·7
(77·4–80·0)
63·5
(59·5–67·5)
35·0
(32·4–37·6)
76·0
(74·2–77·7)
51·7
(48·7–54·7)
85·6
(80·3–90·8)
2000–04 28·2
(25·9–30·6)
61·4
(59·9–62·9)
58·9
(56·6–61·3)
11·8
(9·9–13·7)
14·5
(13·6–15·5)
84·0
(82·8–85·1)
63·8
(59·7–68·0)
35·7
(33·1–38·3)
85·9
(84·7–87·0)
56·0
(53·3–58·8)
87·3
(82·5–92·2)
2005–09 30·4
(28·0–32·9)
63·3
(61·9–64·8)
63·8
(61·5–66·1)
13·6
(11·6–15·7)
16·5
(15·6–17·5)
85·5
(84·4–86·6)
65·4
(61·1–69·6)
37·7
(35·3–40·2)
88·0
(87·0–89·0)
58·1
(55·6–60·7)
88·4
(83·8–93·0)
UK*
1995–99 14·5
(14·1–14·9)
48·1
(47·7–48·5)
49·1
(48·6–49·7)
6·7
(6·1–7·4)
7·3
(7·2–7·5)
74·2
(73·9–74·5)
58·0
(57·1–58·8)
32·8
(32·2–33·3)
68·2
(67·7–68·7)
42·4
(41·7–43·1)
79·1
(77·0–81·2)
2000–04 16·5
(16·0–16·9)
51·4
(51·1–51·8)
53·9
(53·4–54·5)
8·1
(7·5–8·7)
8·5
(8·4–8·7)
78·7
(78·4–78·9)
59·1
(58·2–60·0)
34·5
(34·0–35·0)
80·3
(80·0–80·7)
45·3
(44·6–45·9)
85·9
(84·2–87·7)
2005–09 18·5
(18·0–19·0)
53·8
(53·5–54·2)
56·6
(56·1–57·1)
9·3
(8·7–9·9)
9·6
(9·4–9·8)
81·1
(80·9–81·4)
60·2
(59·3–61·1)
36·4
(35·9–37·0)
83·2
(82·9–83·5)
47·4
(46·7–48·0)
89·1
(87·6–90·7)
(Table 4 continues on next page)
Articles
www.thelancet.com   Vol 385   March 14, 2015 999
between 1995–99 and 2000–04 (from 66% to 61%) was 
based on around 1700 women in each period; the survival 
estimate for women diagnosed during 2005–09 (59%) 
includes data for only 139 women from two registries 
(Calvados, 76%; Loire-Atlantique, 49%); the other 
registries could not provide follow-up data for women 
diagnosed with cervical cancer after 2004 (appendix 
pp 64–80). The striking increase in 5-year survival from 
cervical cancer in China (from 40% to 60%) should be 
interpreted with caution: the estimate for 1995–99 is 
based on data for only 71 women in Changle, Jiashan, 
and Zhongshan, whereas the estimates for 2000–04 
(56%) and 2005–09 (60%) are based on data for more 
than 1200 women (18 registries) and 3900 women 
(21 registries), respectively (appendix pp 64–111).
Data for ovarian cancer are available for 779 302 women 
(table 3). 191 registries in 48 countries contributed data 
for 1995–99, 243 registries in 57 countries had data 
available for 2000–04, and 241 registries in 61 countries 
provided data for 2005–09 (appendix pp 64–80). For 
women diagnosed with ovarian cancer during 2005–09, 
age-standardised 5-year net survival was 40% or higher in 
Ecuador, the USA, nine countries in Asia, and 
eight countries in Europe (table 4; appendix p 148). 
Survival in other countries was mostly in the range 
30–40%, except for Libya (22%). The high survival 
estimate for Gibraltar (59%) is based on data for only 
13 women; it is not age-standardised and the CI is wide 
(table 4); similarly, the very high estimate for Mauritius 
(83%) is based on 52 women diagnosed in 2005. 5-year 
survival for ovarian cancer rose by more than 10% 
between 1995–99 and 2005–09 in Ecuador (from 35% to 
47%), Estonia (from 28% to 39%), and Japan (from 26% 
to 37%), and by 5–10% in Bulgaria, Denmark, France, 
Hong Kong, Iceland, Latvia, and Portugal (appendix 
p 159). More modest increases (2–4%) were seen in 
several countries in South America, Asia, and Europe. 
We were unable to assess any trend in Africa because of 
scant reliable data covering the entire period 1995–2009. 
For women diagnosed with ovarian cancer since 2000, 
data were available from 60 registries in Asia and Central 
and South America (appendix p 170). The range in 5-year 
survival was very wide. The range is much narrower for 
the 160 registries in Europe, North America, and Oceania 
that provided data for the same period.
Data for prostate cancer are available for 4 999 267 men 
(table 3). 189 registries in 48 countries contributed data 
for 1995–99, 241 registries in 57 countries provided 
data for 2000–04, and 240 registries in 60 countries 
had data for 2005–09 (appendix pp 64–80). Among the 
61 countries that provided data on prostate cancer, the 
range in age-standardised 5-year net survival is very 
wide, from less than 40% to greater than 95%. For men 
diagnosed during 2005–09, survival was 90% or higher 
in Austria, Belgium, Brazil, Canada, Cyprus, Ecuador, 
Finland, France, Germany, Israel, Italy, Lithuania, Puerto 
Rico, and the USA (table 4; appendix p 149). In the USA, 
where widespread prostate-speciﬁ c antigen (PSA) testing 
was introduced around 1990, 5-year survival has been 
higher than 90% since 1995–99. Prostate cancer survival 
was 80–89% in 19 countries in Central and South 
America, Asia, Europe, and Oceania. In 18 other 
countries, survival ranged widely (50–79%), but in Libya 
and Mongolia it was 40–41%. Striking and persistent 
Stomach Colon Rectum Liver Lung Breast Cervix Ovary Prostate Leukaemia
(adult)
ALL 
(children)
(Continued from previous page)
Oceania
Australian registries
1995–99 25·9
(24·8–27·0)
60·3
(59·7–61·0)
59·9
(58·9–61·0)
13·2
(11·8–14·6)
13·7
(13·3–14·2)
84·6
(84·0–85·2)
69·9
(68·3–71·6)
36·1
(34·8–37·4)
83·7
(83·1–84·2)
47·5
(46·2–48·7)
82·6
(79·5–85·7)
2000–04 27·8
(26·8–28·9)
63·1
(62·5–63·7)
63·8
(62·9–64·7)
14·3
(13·1–15·4)
14·8
(14·4–15·2)
86·4
(85·9–86·9)
68·4
(66·6–70·3)
37·0
(35·7–38·3)
86·8
(86·3–87·2)
51·0
(49·8–52·1)
86·0
(83·3–88·6)
2005–09 27·9
(26·7–29·0)
64·2
(63·6–64·8)
64·2
(63·3–65·1)
14·7
(13·5–16·0)
15·0
(14·6–15·5)
86·2
(85·6–86·8)
67·1
(65·1–69·1)
37·5
(36·2–38·8)
88·5
(88·1–88·9)
51·1
(50·0–52·3)
88·6
(85·9–91·4)
New Zealand*
1995–99 22·2
(20·0–24·3)
60·8
(59·5–62·1)
57·0
(54·8–59·3)
11·6
(8·5–14·6)
12·2
(11·3–13·1)
79·5
(78·2–80·8)
64·3
(60·8–67·9)
35·8
(33·0–38·5)
80·8
(79·6–82·0)
47·7
(45·0–50·4)
82·6
(76·0–89·2)
2000–04 24·6
(22·4–26·8)
60·9
(59·6–62·1)
59·8
(57·8–61·9)
12·9
(10·3–15·5)
11·4
(10·6–12·2)
82·3
(81·1–83·5)
67·6
(64·0–71·2)
38·7
(36·0–41·3)
88·5
(87·6–89·4)
60·2
(57·9–62·4)
85·8
(79·9–91·7)
2005–09 26·7
(24·3–29·0)
61·6
(60·4–62·8)
60·8
(58·8–62·8)
17·4
(14·6–20·2)
12·4
(11·6–13·3)
83·7
(82·5–84·9)
63·9
(60·2–67·6)
33·8
(31·3–36·2)
88·7
(87·7–89·6)
58·0
(55·6–60·3)
89·3
(83·8–94·8)
 Data are net survival estimates (%) with 95% CI. Italics denote survival estimates that are not age-standardised. When too few patients were available for analysis in any calendar period, data were merged and the survival 
estimates are underlined. Follow-up was shorter than 5 years for six registries: Libya (Benghazi); The Gambia; Argentina (Mendoza); China (Lianyungang); Indonesia (Jakarta); and Colombia (Manizales: stomach, colon, 
breast, cervix, and prostate). ALL=acute lymphoblastic leukaemia. *100% coverage of the national population. †100% coverage of the national population for childhood leukaemia only. ‡South Korea. §Survival estimate 
considered less reliable.
Table 4: 5-year age-standardised net survival for adults (aged 15–99 years) diagnosed with one of ten common malignant diseases and children (aged 0–14 years) with ALL, by continent, 
country, and calendar period of diagnosis
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increases in prostate cancer survival were seen in many 
countries between 1995–99 and 2005–09 (appendix 
p 160). Survival rose by 10–20% in 22 countries in 
Central and South America, Asia, and Europe; smaller 
increases (less than 10%) were seen in 15 countries.
Data for leukaemia in adults are available for 
873 588 patients (table 3). 185 registries in 47 countries 
provided data for 1995–99, 234 registries in 56 countries 
contributed data for 2000–04, and 232 registries in 
60 countries provided data for 2005–09 (appendix 
pp 64–80). For adults diagnosed with leukaemia during 
2005–09, age-standardised 5-year net survival was 
50–60% in 21 countries in North America, west Asia, 
Europe, and Oceania (table 4; appendix p 150). The 
estimate in Mauritius (57%) is based on 31 patients 
diagnosed in 2005; it is not age-standardised and has a 
wide CI. Similarly, the estimate for Cuba (60%) is based 
on only 97 patients diagnosed during 1998–2006. 5-year 
net survival from adult leukaemia is generally much 
lower in the 15 participating Asian countries than in 
other regions of the world (appendix pp 163–73). With a 
few exceptions, survival seems to be low in east Asia (eg, 
from 19% in Japan to 23% in South Korea and Taiwan), 
high in west Asia (eg, from 33% in Turkey to 53% in 
Qatar), with a mixed picture in other Asian countries (eg, 
from 7% in Jordan to 40% in Indonesia). Survival 
estimates for adult leukaemia from Jordan, India, and 
Saudi Arabia might be less reliable for international 
comparison, but the overall pattern of leukaemia survival 
in Asia is still informative. Survival increases of 10–16% 
for adult leukaemia were seen in China, Denmark, 
Germany, Iceland, Latvia, Sweden, and New Zealand. 
Smaller rises of 5–9% were noted in North America, 
Israel, Japan, South Korea, and ten European countries. 
In Malta, 5-year survival fell from 39% in 1995–99 (based 
on 142 adults) to 19% for 2005–09 (128 adults; appendix 
p 161). This pattern is surprising, because data quality is 
very high (appendix pp 54–58) and survival trends for all 
solid tumours seem to be normal. Smaller declines were 
seen in several countries, such as Slovakia (from 41% to 
37%) and Slovenia (from 44% to 38%).
Data for acute lymphoblastic leukaemia in children are 
available for 74 343 patients (table 3). 173 registries in 
42 countries contributed data for 1995–99, 215 registries in 
50 countries provided data for 2000–04, and 213 registries 
in 53 countries provided data for 2005–09. In Romania 
(Cluj), data were only available for eight children and 
survival was not estimated. Of 53 countries, 32 provided 
data with 100% national population coverage. The 
geographic range in survival for acute lymphoblastic 
leukaemia in children was very wide. For patients 
diagnosed during 2005–09, age-standardised 5-year net 
survival was 90% or higher in Austria, Belgium, Canada, 
Germany, and Norway and 80–89% in 21 countries on 
various continents (table 4; appendix p 151). In many 
countries, however, 5-year net survival is still lower than 
60%, even after adjustment for the very high background 
mortality in childhood. Survival was less than 50% in 
Indonesia, Mongolia, and Lesotho, although these 
estimates are based on very small numbers. The range of 
survival estimates for childhood acute lymphoblastic 
leukaemia in Central and South America (16 registries) 
and Asia (23 registries) is much lower than the range in 
North America (48 registries), Europe (83 registries), and 
Oceania (seven registries; appendix p 173). 5-year survival 
for childhood acute lymphoblastic leukaemia rose by 10% 
or more between 1995–99 and 2005–09 in Belarus, 
Belgium, Bulgaria, China, Colombia, Lithuania, Norway, 
Portugal, South Korea, Spain, Taiwan, and the UK. The 
estimate of 11% from China for 1995–99 is based on only 
23 children, but the increase from 50% for 2000–04 to 61% 
for 2005–09 is more reliable. Increases in survival of up to 
9% were seen in 16 other countries. 5-year survival in 
Argentina, Ecuador, and Slovakia was in the range 60–79%, 
with little or no change over time. Survival seemed to fall 
in Brazil (from 72% to 66%), Malaysia (from 77% to 69%), 
and Slovenia (from 83–86% in 1995–2004 to 76% for 
2005–09). Survival trends could not be assessed in Africa.
Discussion
With CONCORD-2, we have initiated worldwide 
surveillance of trends in cancer survival. In the ﬁ rst 
CONCORD study,6 comparable estimates of cancer 
survival worldwide were provided: the study included 
1·9 million patients diagnosed with breast, colorectal, or 
prostate cancer during 1990–94 and followed up to 1999 in 
31 countries (panel). CONCORD-2 extends coverage to 
25·7 million patients diagnosed with an invasive primary 
cancer during the 15-year period 1995–2009 in 67 countries. 
The ten index cancers represent about two-thirds of 
the overall cancer burden in both low-income and high-
income countries.4 Individual patient data provided by 
279 population-based cancer registries were prepared with 
standardised quality-control procedures and subjected to 
centralised analysis with the latest statistical methods.
The ﬁ ndings do not cover all countries, but they provide 
at least some population-based cancer survival estimates 
for 67 countries (26 of low or middle income) that are 
home to two-thirds of the world’s population, including 
national data for 40 countries. The estimates are derived 
from analysis of raw data on the survival of individual 
cancer patients up to 5 years after diagnosis. Until now, 
for comparison of global or continental survival, 
researchers generally needed to interpret scattered 
reports produced with diverse cancer deﬁ ni tions, 
quality-control criteria, and survival estimators, for 
diﬀ erent calendar periods, and age-standardised to 
diﬀ erent sets of weights.46 More speculative comparisons 
have been based on modelling of mortality-incidence 
ratios, sometimes with data from neighbouring regions 
or countries,47 with all the attendant assumptions.48
Even after adjustment for the wide international 
variation in levels of mortality from other causes, and 
with due allowance for variation in quality of data, the 
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global range in 5-year survival from ten cancers in adults 
and acute lymphoblastic leukaemia in children is very 
wide. For most cancers, survival in Africa, Asia, and 
Central and South America is lower, and the range in 
survival much wider, than in Europe, North America, 
and Oceania. The wider range is only partly attributable 
to the fact that not all cancer registries could provide data 
covering the 15 years from 1995 to 2009; for example, 
many of the Chinese registries contributed data for 
2000–04 but not 2005–09. In North America and Oceania, 
population coverage was higher than 80% and the same 
registries generally provided data for the entire period 
1995–2009 (ﬁ gure 4; appendix pp 163–73): survival for 
most cancers was high on a global scale, with a fairly 
narrow range in estimates between registries.
5-year net survival from stomach cancer is generally in 
the range 25–30%, but it is very high (50–60%) in Japan, 
South Korea, and, to a lesser extent, Taiwan. High 
survival from stomach cancer in Japan,49 South Korea,50 
and Taiwan51 is well known, and is likely to be attributable 
to intensive diagnostic activity, early stage at diagnosis, 
and radical surgery. Survival varies according to sub-site, 
morphological type, and stage. Types of cancer with 
better prognosis might also be more common in Japan 
and South Korea, but the striking worldwide diﬀ erences 
in survival suggest important lessons could be learnt 
from these countries about diagnosis and treatment.
5-year survival has risen for colon and rectal cancers in 
most developed countries and regions, including North 
America, Europe, Oceania, and parts of east Asia (South 
Korea and urban areas in China); increases in breast 
cancer survival have also been noted in these regions and 
in parts of Central and South America. These trends are 
likely to be attributable to earlier diagnosis, reduction in 
postoperative mortality,52 and more eﬀ ective treatment.53,54 
For rectal cancer, preoperative radiotherapy and total 
mesorectal excision reduce local recurrence and extend 
survival,55–57 which could account for improvements 
noted in Canada, Finland, the Netherlands, Norway, 
Sweden, and the USA, where survival was already high 
(55–60%) for patients diagnosed in 1995–99 and rose 
further for those diagnosed during 2005–09 (62–65%). 
These trends accord with those reported from the 
Netherlands,58 Scotland, the Nordic countries,59 and 
elsewhere in Europe.60
Liver and lung cancer remain lethal in both developing 
and developed countries, with 5-year survival generally 
lower than 20%, indicating that most patients are still 
diagnosed when they are inoperable. Primary prevention 
aimed at reducing tobacco and alcohol consumption, and 
prevention of chronic hepatitis, will be especially 
important for these cancers. The very low survival estimate 
for liver cancer in The Gambia (5%) is based on a sample 
of only 85 patients diagnosed during 1995–97 who were 
followed up for less than 5 years, to the end of 1998; it is 
not age-standardised, but it is unlikely to be far wrong: 
patients in The Gambia tend to present with very advanced 
disease and cirrhosis and are not amenable to surgery.61 
Overall completeness of registration is low, but the 
incidence of liver cancer is comparable with that of other 
west African populations.62 Data from the national cancer 
registry for The Gambia, set up in 1986 to support the 
IARC’s Gambia Hepatitis Intervention Study,63 have been 
analysed previously,64 but more recent data were 
unavailable, so we cleaned and analysed them here 
alongside all other datasets, with permission from IARC.
The global range in 5-year survival from cervical cancer 
is very wide, from less than 40% to more than 70%. The 
overall decline in survival from 66% to 61% in France 
between 1995–99 and 2000–04 was seen in all nine 
registries (appendix p 105). The decrease might be 
attributable to removal of less aggressive tumours by 
more intensive cervical screening for preinvasive 
lesions.65,66 Survival from cervical cancer in the Nordic 
countries was stable or rose slightly over the same 
period.67 By comparison, lower survival in low-income 
and middle-income countries is striking, since invasive 
cervical cancer is potentially curable with early detection 
by screening and appropriate surgery.68
5-year survival from ovarian cancer is generally in the 
range 30–40% in most parts of the world, but the overall 
range is much wider. Diversity in international survival 
might be attributable partly to variations in the proportion 
of tumours classiﬁ ed as type I (typically early-stage and 
slow-growing) and type II (typically late-stage and 
aggressive).69 Diﬀ erences in stage at diagnosis and 
treatment are also likely to be important.70 Diﬀ erential 
Panel: Research in context
Systematic review
In the ﬁ rst global comparison of population-based cancer survival (CONCORD),6 wide 
variations in survival from cancers of the breast (women), colon, rectum, and prostate 
were reported among 1·9 million adults diagnosed during 1990–94 and followed up to 
1999 in 31 countries (16 countries had national coverage). More recent studies have 
diﬀ ered with respect to geographic and population coverage, calendar period, and 
analytical methods, and they do not enable worldwide comparison of survival trends.7–9 
With CONCORD-2, we have extended coverage to 25·7 million cancer patients diagnosed 
during the 15-year period 1995–2009 in one of 67 countries (26 of low or middle 
income), of which 40 countries had national coverage.
Interpretation
The ten index cancers we selected for analysis represent two-thirds of the overall cancer 
burden in both low-income and high-income countries. 5-year survival from colon, rectal, 
and breast cancers has increased in most developed countries. Liver and lung cancer 
remain lethal in both developing and developed countries. Striking increases in prostate 
cancer survival have occurred in many countries, but trends vary widely. The range in 
cervical and ovarian cancer survival is very wide, but improvements have been slight. In 
east Asia, stomach cancer survival is very high, suggesting lessons could be learnt, 
whereas survival for adult and childhood leukaemia is remarkably low. The global range in 
survival from precursor-cell acute lymphoblastic leukaemia in children is very wide, 
suggesting major deﬁ ciencies in the management of what is now a largely curable 
disease. The ﬁ ndings of our study can be used to assess the extent to which investment in 
health-care systems is improving their eﬀ ectiveness.
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classiﬁ cation of borderline and invasive tumours might 
also contribute. Overall, however, worldwide survival 
trends show very little improvement between 1995–99 
and 2005–09 (appendix p 158). This ﬁ nding accords with 
the absence of improvement reported from many 
developed countries.7,9
Striking increases in 5-year survival from prostate 
cancer have occurred in many countries, but global 
trends varied widely. Examples include three northern 
European countries, all with nationwide cancer 
registration. 5-year survival in Lithuania jumped from 
52% for men diagnosed during 1995–99 to 92% for 
those diagnosed during 2005–09. The rise in Latvia was 
from 52% to 74%: access to health care in these 
countries has improved, and opportunistic PSA 
screening began in 2000.71 In Denmark, survival rose 
from 46% to 77% over the same period, having been 
stable at 40% throughout the period 1982–94,72 during 
which time survival increased rapidly in the other four 
Nordic countries.73 The Danish Urology Society advised 
against PSA testing in asymptomatic men in the early 
1990s,74 but this advice is now followed less widely. 
By contrast, survival in North America and Oceania was 
already very high in the late 1990s, and increases since 
then have been much smaller. In Africa, we were 
unable to assess a trend.
Survival from both adult and childhood leukaemia in 
east Asia is surprisingly low. The low survival for adult 
leukaemia in Japan, South Korea, and Taiwan is especially 
surprising, because survival from solid tumours is 
generally high. Could ethnic or genetic factors play a part? 
This possibility has been suggested in a recent comparison 
of survival from chronic lymphocytic leukaemia between 
Taiwan and the USA.75 Leukaemia survival is also low in 
China, but haematological malignant diseases have 
received low priority in cancer control there, with limited 
access to health insurance and chemotherapy,76 and 
medical resources in rural areas are poor.77
The global range in 5-year survival from acute 
lymphoblastic leukaemia in children is very wide, from 
less than 60% in several countries to 90% or higher in 
Austria, Belgium, Canada, Germany, and Norway. This 
ﬁ nding conﬁ rms that major deﬁ ciencies are present in 
the management of what is now a largely curable disease.78 
Failure to start or complete treatment, usually for ﬁ nancial 
reasons, is an important contributor to the survival deﬁ cit 
in developing countries.79
Standardised quality controls were applied system-
atically to all datasets. Detailed discussions were held 
with every registry to identify and correct any errors or 
artifacts in the data. Many registries resubmitted their 
data after correction, which greatly improved data 
quality and comparability. The overall proportion of 
eligible tumours excluded from analysis was low 
(3·6%), but it was much higher for some registries and 
varied widely between cancers. For some populations, 
mostly in low-income and middle-income countries, 
these exclusions will have biased survival estimates 
upwards. Thus, the proportion of cancer registrations 
from a death certiﬁ cate only was typically higher in 
countries where survival is low. This leads to exclusion 
from analysis of a group of patients who tend to have 
low survival,80 leading to overestimation of the level of 
survival in that population. This bias would tend to 
reduce international diﬀ erences.
Various indications suggest that the data submitted by 
some registries were not exhaustive, either because there 
were fewer cancer patients than expected or because the 
full range of haemopoietic malignant diseases was not 
represented in some of the leukaemia datasets. The 
smaller number of cancer registrations in Poland for 
1995–99 reﬂ ects a national strike of doctors in 1997, but 
we have little reason to suppose this type of 
incompleteness would bias survival estimates.
Pathological conﬁ rmation of diagnosis was available 
for more than 90% of cancers included in the analyses 
(98·5% for childhood acute lymphoblastic leukaemia), 
and less than 4% of malignant diseases were assigned to 
a non-speciﬁ c morphology code. Nevertheless, consider-
able variation was noted, and pathological evidence was 
much less complete for some populations in low-income 
and middle-income countries (table 2; appendix pp 3–63).
Several registries reported high proportions of intestinal-
type adenocarcinoma in the colon and rectum: this 
morphological type was originally described (in 1965) for 
carcinoma of the stomach81 and is included in ICD-O-3 
(M8144). A similar issue arose with cholangiocarcinoma 
(M8160) coded as arising in the liver (ICD-O-3 site code 
C22.0) rather than the intrahepatic bile duct (C22.1). If we 
were told that pathologists frequently use these terms for 
malignant disease of the large bowel or liver, respectively, 
we included the patients in our analyses.
The distribution of cancers within an organ by anatomic 
sub-site or morphological type can diﬀ er between 
populations, so any diﬀ erences in survival by sub-site or 
morphological features could aﬀ ect comparisons of overall 
survival. We will address the eﬀ ect on survival of these 
diﬀ erences in biology with more detailed analyses, 
particularly for cancers of the stomach, lung, and ovary. 
Leukaemia comprises a broad and heterogeneous group of 
diseases. We excluded chronic myeloid leukaemia; survival 
for other major groups will be investigated in more detail.
Premalignant and small malignant lesions can be 
detected more frequently in countries with mass 
screening programmes or intensive early diagnostic 
activity, particularly for cancers of the breast, cervix, 
colon, rectum, and prostate. Diﬀ erences in tumour stage 
at diagnosis can contribute to international variations in 
overall survival between low-income countries.8 Wide 
diﬀ erences in tumour stage at diagnosis and 
stage-speciﬁ c survival have also been recorded among 
high-income countries.59,70,82–84 High-resolution studies of 
tumour stage at diagnosis, treatment, and adherence to 
guidelines have helped account for international 
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diﬀ erences in survival.55,85–87 The comparability of data 
gathered routinely on cancer stage remains poor 
in developed countries,88 even though the TNM 
classiﬁ cation89 has been available for more than 60 years. 
We will examine in more detail the extent to which 
available data on tumour stage can explain the very wide 
global diﬀ erences in survival reported by us here.
We imputed the day of diagnosis in data from registries 
that only record (or were only allowed to submit) the 
month and year of diagnosis. A few of those registries 
also submitted survival time in days; our imputation 
achieved similar results. The eﬀ ect on short-term survival 
of minor variations in the date of diagnosis is generally 
small90 and cannot account for the very wide international 
diﬀ erences in 5-year survival.91
Loss to follow-up of cancer patients in registries using 
active follow-up varied widely, but most registries also 
used several passive follow-up techniques. Diﬀ erences 
between the databases used for passive follow-up can 
aﬀ ect survival estimates.92,93 When information for all 
deaths is incomplete or inaccessible from administrative 
systems, active follow-up by the registry augments 
completeness of ascertainment of vital status, particularly 
in low-income and middle-income countries.94 Some 
registries did not have the resources to follow up all their 
patients for vital status. Others could not provide 
follow-up data for at least 5 years after diagnosis for all 
their patients; for those registries, we have presented 
survival at 3 or 4 years if possible.
If age-speciﬁ c (and thus age-standardised) survival 
estimates could not be produced, non-standardised 
estimates for all ages combined were presented. 
In some analyses, data had to be pooled across two or 
three calendar periods, restricting presentation of 
survival trends. For some countries or regions with very 
small populations, no survival estimate could be made 
at all for less common cancers, because very few 
patients were available for analysis.
We used a rigorously enforced protocol, with centralised 
data evaluation and analysis to enhance comparability, 
but international survival comparisons should still be 
interpreted with caution. Data quality varies widely:95,96 
we provided detailed indices of data quality at country 
and registry level (table 2; appendix pp 3–63), which 
should be taken into account. Not all countries could 
provide data for 2005–09. Also, the range in size between 
the smallest and largest populations included in this 
report is greater than 1000-fold, both for registries with 
national coverage (eg, Gibraltar includes 29 000 people 
and the UK covers 61·8 million people) and those with 
regional coverage (eg, Nunavut in Canada represents 
33 000 people whereas California in the USA includes 
37·0 million people). These diﬀ erences are reﬂ ected in 
the numbers of patients and the width of CIs around 
survival estimates. However, lack of precision because of 
small numbers does not necessarily imply that the 
survival estimates are incorrect or unreliable: high 
quality and completeness of data and follow-up can be 
easier to achieve in small or island populations than in 
large urban populations.
For robust international comparison of cancer survival, 
diﬀ erences and trends in background mortality according 
to age, sex, region, and ethnic origin must be taken into 
account. In the populations covered by these data, the 
range in background mortality was very wide, measured by 
life expectancy at birth (46–87 years in females and 
45–81 years in males), and by the change in life expectancy 
between 1995 and 2009 (appendix p 175), and in other 
metrics such as the probability of death in middle age (data 
not shown). We created more than 6500 complete life 
tables of background mortality to capture these diﬀ erences.
For children with cancer, usual practice is to present the 
observed probability of survival, including all causes of 
death,97 rather than net survival, because mortality from 
other causes is typically very low, at least in developed 
countries. Here, however, we have estimated net survival 
for children with acute lymphoblastic leukaemia because, 
among the 53 countries for which data could be analysed, 
mortality from other causes in childhood varied very widely. 
In 2002, infant mortality ranged from less than one death 
per 1000 livebirths to more than 120 deaths per 
1000 livebirths (in some African populations); under-5 
mortality ranged from less than one death per 1000 livebirths 
to more than 200 deaths per 1000 livebirths; and the overall 
probability of death before age 15 years ranged from 
one death per 1000 livebirths to more than 250 per 
1000 livebirths (data not shown). For a worldwide 
comparison of survival from childhood acute lymphoblastic 
leukaemia, it seemed especially important to eliminate the 
eﬀ ect of this wide variation in background mortality 
between countries and over time.
Net survival was age-standardised in most estimates 
for both adults and children. Age standardisation 
minimises the risk of reporting international diﬀ erences 
or trends in cancer survival that are attributable solely to 
international diﬀ erences or changes over time in the age 
distribution of cancer patients.42
We included both ﬁ rst and higher order cancers in our 
analyses. The eﬀ ect of multiple primary cancers on overall 
survival is typically only 1–2%,98 but the proportion of such 
cancers in a given population is aﬀ ected by the set of rules 
used to deﬁ ne them99 and by the longevity of the registry.100 
Some participating registries began operation in the 1950s 
whereas others only started after 2000. In long-established 
registries, 10% or more of patients might be registered 
with more than one cancer.101 This proportion is lower in 
newer registries, because a second cancer will typically be 
registered as the patient’s ﬁ rst. Restriction to ﬁ rst primaries 
can also aﬀ ect international comparison of survival trends, 
because the number of long-term survivors at high risk of 
another cancer is increasing, particularly in high-income 
countries.102 Exclusion of second cancers would, therefore, 
tend to bias international survival comparisons in favour 
of wealthier countries.103 The rules for deﬁ ning multiple 
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primary cancers diﬀ er between North America and the 
rest of the world,24,25 but in a novel step, data from registries 
in North America were ﬁ rst converted to IACR deﬁ nitions 
used elsewhere, before being submitted for analysis. This 
alteration will have minimised any eﬀ ect on international 
survival comparisons presented here.
To maintain the breadth of global surveillance of 
survival, we retained some datasets that seemed less 
suitable for international comparison than all other 
estimates, but we ﬂ agged these survival estimates to 
inform interpretation. The number of ﬂ agged estimates 
is larger than in the ﬁ rst CONCORD study6 because more 
registries are from low-income countries and the data 
cover a much longer period. Residual errors and artifacts 
in data undoubtedly exist, but they are unlikely to account 
for global patterns and trends in cancer survival.
We used an unbiased estimator of net survival.104 To our 
knowledge, this is the ﬁ rst time this estimator has been 
used for an international comparison. We used the period 
approach33 to estimate survival up to 5 years after diagnosis 
for patients diagnosed during 2005–09 (appendix p 174). 
This approach oﬀ ers reliable prediction of the eventual 
survival of recently diagnosed patients who have not all 
been followed up for 5 years.105
A small part of the global range in survival could be 
attributable to diﬀ erences in the intensity of diagnostic 
activity. The introduction of new diagnostic techniques in 
wealthier countries, such as PSA testing for prostate 
cancer, has led to more patients being diagnosed at an 
early stage of disease, typically with a good prognosis, thus 
inﬂ ating both incidence and survival. We were not able to 
use the proportion of in situ cancers for international 
comparison of the intensity of diagnostic activity for 
cancers of the colon, rectum, breast, cervix, or prostate. 
Some registries do not collect data for in situ tumours, 
whereas some registries that do collect this information 
did not include these data in their submissions. In poorer 
countries, by contrast, many patients still die undiagnosed 
or untreated.68 
For some cancers, both incidence and survival in 
countries with the most intensive diagnostic activity could 
be inﬂ ated slightly by overdiagnosis, but the eﬀ ect on the 
global range of survival estimates is probably small. 
Equally, in the poorest countries, under-registration of 
cancer patients with the worst prognosis might lead to 
underestimation of incidence and overestimation of 
survival. Even though some survival estimates in 
low-income and middle-income countries might be too 
high for this reason, it is striking that for cancers of the 
colon, rectum, lung, and breast, and particularly for 
leukaemia in adults and children, the range of estimates 
in Africa and Central and South America for patients 
diagnosed during 2005–09 is still much lower than in 
North America and Oceania during 1995–99, 10 years 
earlier (ﬁ gure 4; appendix pp 163–73). As reported 
elsewhere,68 these patterns strongly suggest inadequate 
access to early diagnosis and optimum treatment.
National health-care systems must manage all cancer 
patients, however they are diagnosed, even if some patients 
might not have been diagnosed before widespread 
adoption of new diagnostic techniques or screening 
programmes. In a given country, incidence and survival 
estimates reﬂ ect current approaches to prevention, 
diagnosis, and treatment.6 Coherent assessment of 
preventive and health-care strategies, therefore, requires 
that all cancer patients are included, no matter how they 
are diagnosed, in both incidence and survival estimates. 
Projections of the future burden of cancer106 are based on 
the same cancer incidence data.
Some cancer registries followed up their patients for 
the ﬁ rst time so they could participate in CONCORD-2. 
Other registries, not all of them in low-income countries, 
were prevented from participating by scant resources 
either to follow up registered patients for vital status or to 
prepare data for submission. This deﬁ cit underscores the 
continued fragility, low coverage, and scarcity of 
resources for cancer registries.4,107,108 In many countries, 
even the basic infrastructure of a civil registration system 
and vital statistics is deﬁ cient.109 This absence is especially 
severe in Africa, where several participating countries 
have also been subject to civil or military conﬂ ict within 
the past 10–15 years and where, with few exceptions, 
assessment of recent survival trends from available data 
was almost impossible.
Cancer registries are crucial to our understanding of 
the global cancer burden,107 and they need to be funded 
and equipped to gather, analyse, and publish incidence 
and survival data at national or regional level. Worldwide 
monitoring of cancer incidence has been done since the 
1960s, with centralised data collection and standardised 
methods in Cancer Incidence in Five Continents.16 IARC’s 
Global Initiative for Cancer Registry Development is an 
important stimulus to promote high-quality data 
collection and cancer registration in low-income and 
middle-income countries.108
Both WHO3 and the UN110 have recognised cancer as a 
worldwide public health issue of growing concern. 
However, if cancer registration is to develop further in 
support of the 25 × 25 goals and in the evaluation of 
clinical care,111 WHO and the UN will need to address 
the growing legal and procedural diﬃ  culties in 
obtaining primary health data and in accessing them for 
research. For example, legislation now at the ﬁ nal stage 
of discussion in the European Union would make 
cancer registration and most forms of public health 
research either impossible or illegal in 28 European 
countries.112,113
The CONCORD programme at the London School of 
Hygiene & Tropical Medicine (LSHTM) represents the 
establishment of worldwide surveillance of cancer 
survival by centralised quality control and analysis of 
population-based registry data, as a comparative metric 
of the eﬀ ectiveness of health systems. It will provide part 
of the evidence base for global policy on cancer control 
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and should contribute to the overarching goal of the 
World Cancer Declaration 201314 and, more broadly, to 
the “revolution in metrics for global health”.114
At a national level, cancer outcomes are aﬀ ected by the 
organisation and funding of access to health services.115 
Improvements in cancer survival have been reported 
after major political and economic changes in Estonia,116 
Lithuania,117 and Germany.118 In turn, low survival has 
aﬀ ected the development of cancer strategy in countries 
such as Algeria,119 Brazil,120,121 Mexico,122 China, India, and 
Russia,123 and in many wealthier countries.4
Some of the conclusions drawn from these analyses 
are similar to those for patients diagnosed 20–25 years 
ago.6 The ﬁ ndings of this study can be used to assess the 
extent to which investment in health-care systems is 
improving their eﬀ ectiveness. We will examine survival 
trends and diﬀ erentials in relation to health economic 
indicators to assess why improvements in survival are so 
slow and unequal.
Most of the wide global range in cancer survival is 
probably attributable to inequity in access to optimum 
diagnostic and treatment services,6 both in rich124–126 and 
poor127,128 countries. Availability of linear accelerators varies 
more than ten-fold worldwide, from one machine per 
500 000 population to less than one per ﬁ ve million people, 
and more than 30 countries in Africa and Asia have no 
radiotherapy service at all.129 Cancer survival in Europe has 
been associated with gross national product, total national 
expenditure on health and investment in health technology 
(eg, CT scanners, radiotherapy units),130 and with 
suboptimum allocation of available resources.86 The global 
economic cost of cancer from premature death and lost 
productivity was estimated at US$895 billion in 2008, 
excluding direct treatment costs estimated at $300 billion.131 
Even in wealthy countries, the rapidly growing costs of 
cancer treatment have raised concerns about the growing 
use of tests, imaging, and treatments that are expensive 
but have marginal value.132 At the same time, closing the 
rich–poor divide in access to cancer treatment has been 
described as “an equity imperative”.133,134 The ﬁ ndings 
reported here conﬁ rm the global divide in outcomes.
The ﬁ rst international study of cancer survival was 
published 50 years ago.5 In the same year, 
Alexander Langmuir, founder of the US Centers for 
Disease Control and Prevention’s epidemic intelligence 
service, commented on national outbreaks of infectious 
disease: “good surveillance does not necessarily ensure 
the making of the right decisions, but it reduces the 
chances of wrong ones”.135 His view applies today to 
non-communicable diseases such as cancer, for which 
long-term surveillance of incidence, mortality, and 
survival is increasingly important. Survival is a key metric 
of overall progress in cancer control.4 Continuous 
worldwide surveillance of cancer survival should become 
both an indispensable source of information for cancer 
patients and researchers and a stimulus for politicians to 
improve health policy and health-care systems.
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